Influenza Virus Vaccine

also known as Fluzone · Influenza vaccine · Fluarix · Vaxigrip · trivalent inactivated influenza vaccine · Trivalent Influenza Vaccine · TIV · Fluzone Quadrivalent · +119 more

Vaccine

Developed for: influenza · disease related to solid organ transplantation · acute myeloid leukemia · aplastic anemia · ischemic stroke · myocardial infarction · brain hypoxia - ischemia · cerebral palsy
+66 more
· chronic lymphocytic leukemia/small lymphocytic lymphoma · disease related to hematopoietic stem cell transplant · heart failure · inflammatory bowel disease · myelodysplastic syndrome · plasma cell myeloma · breast cancer · coronary artery disorder · hematopoietic and lymphoid cell neoplasm · HER2 positive breast carcinoma · Hodgkins lymphoma · infertility disorder · leukemia · stroke disorder · acute coronary syndrome · acute myelomonocytic leukemia M4 · apraxia · autism · autism spectrum disorder 1 · B-cell chronic lymphocytic leukemia · bone marrow disorder · bone marrow failure syndrome · central nervous system neoplasm · chronic myeloid leukemia · chronic obstructive pulmonary disease · colorectal cancer · congenital muscular dystrophy · cutaneous melanoma · diffuse midline glioma, H3 K27M-mutant · digestive system cancer · Duchenne muscular dystrophy · female breast carcinoma · global developmental delay with or without impaired intellectual development · habitual spontaneous abortion · hydrocephalus · infectious disease · major depressive disorder · male breast carcinoma · malignant pancreatic neoplasm · metastatic melanoma · neonatal anemia · pancreatic adenocarcinoma · pneumonia · respiratory tract infectious disorder · scleroderma · severe combined immunodeficiency · sickle cell disease · skin squamous cell carcinoma · spinal muscular atrophy · systemic lupus erythematosus · traumatic brain injury · triple-negative breast carcinoma · viral infectious disease · acute myocardial infarction · allergic disease · asthma · atopic eczema · autoinflammatory syndrome · avian influenza · bronchopulmonary dysplasia · cerebrovascular disorder · necrotizing enterocolitis · newborn respiratory distress syndrome · primary viral infectious disease · retinopathy of prematurity · type 1 diabetes mellitus
Investigated by: National Institute of Allergy and Infectious Diseases (NIAID) · Sanofi Pasteur, a Sanofi Company · GlaxoSmithKline · Stanford University · Centers for Disease Control and Prevention · Emory University
+325 more
· National Cancer Institute (NCI) · China National Biotec Group Company Limited · Duke University · Joanne Kurtzberg, MD · Novartis Vaccines · Sanofi · Seqirus · Abbott Biologicals · Changchun Institute of Biological Products Co., Ltd. · Chengdu Institute of Biological Products Co.,Ltd. · Children's Hospital Medical Center, Cincinnati · PATH · Solvay Pharmaceuticals · University of Witwatersrand, South Africa · Washington University School of Medicine · Bill and Melinda Gates Foundation · Canadian Institutes of Health Research (CIHR) · Guizhou Center for Disease Control and Prevention · H. Lee Moffitt Cancer Center and Research Institute · MCM Vaccines B.V. · National Institutes of Health (NIH) · Novartis · Novavax · Quintiles, Inc. · Roswell Park Cancer Institute · Taian City Central Hospital · Tel-Aviv Sourasky Medical Center · University of North Carolina, Chapel Hill · Vanderbilt University Medical Center · Asfendiyarov Kazakh National Medical University · Assistance Publique - Hôpitaux de Paris · AstraZeneca · Baylor College of Medicine · Beijing Institute of Biological Products Co Ltd. · Bundang CHA Hospital · Celgene Corporation · Center for Human Reproduction · Centers for Disease Control and Prevention, China · Colby Pharmaceutical Company · Dana-Farber Cancer Institute · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Foundation for Human Reproduction · French National Institute of Health and Medical Research · Guangzhou First People's Hospital · Hebei Provincial Center for Diseases Control and Prevention · Henan Center for Disease Control and Prevention · Hunan Provincial Center for Disease Control and Prevention · Institut Pasteur · Institute of Medical Biology, Chinese Academy of Medical Sciences · International Centre for Diarrhoeal Disease Research, Bangladesh · Janssen Vaccines & Prevention B.V. · Jining First People's Hospital · Johns Hopkins University · Linyi People's Hospital · M.D. Anderson Cancer Center · Makerere University · MedImmune LLC · National Heart, Lung, and Blood Institute (NHLBI) · National Institutes for Food and Drug Control, China · Northwestern University · Peking University · PharmaJet, Inc. · Protein Sciences Corporation · Research Institute for Biological Safety Problems · Research Institute for Development · Research Institute of Influenza, Russia · Ruijin Hospital · Seattle Children's Hospital · Shahid Beheshti University of Medical Sciences · Shandong Qilu Stem Cells Engineering Co., Ltd. · Shandong University of Traditional Chinese Medicine · Sichuan Center for Disease Control and Prevention · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tan Tock Seng Hospital · all 331 on the full record

Trials 300 · started per year

today

1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 04 trials
Phase 0	NCT06664151	Nov 2024 → Aug 2026 overdue	skin squamous cell carcinoma	Dana-Farber Cancer Institute	Recruiting	No outcome recorded
Phase 0	NCT03449459	Dec 2018 → Dec 2020	chronic obstructive pulmonary disease	Shanghai Zhongshan Hospital	Completed	No outcome recorded
Phase 0	NCT03748524	Oct 2018 → Sep 2021	—	Washington University School of Medicine	Completed	No outcome recorded
Phase 0	NCT04484532	Oct 2017 → Jun 2022	acute myeloid leukemia, myelodysplastic syndrome	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 128 trials
Phase 1	NCT06229392	Jun 2026 → Jun 2027	triple-negative breast carcinoma	Rush University Medical Center	Withdrawn	No outcome recorded
Phase 1	NCT06355232	May 2024 → Dec 2025 overdue	COVID-19, influenza	Vaxine Pty Ltd	Recruiting	No outcome recorded
Phase 1	NCT05577611	Aug 2022 → Dec 2024	acute myeloid leukemia	Zhongnan Hospital	Unknown	No outcome recorded
Phase 1	NCT05163847	Jun → Nov 2022	—	FluGen Inc	Completed	No outcome recorded
Phase 1	NCT04943848	Jan 2022 → Sep 2026 expected	diffuse midline glioma, H3 K27M-mutant	Ann & Robert H Lurie Children's Hospital of Chicago	Recruiting	No outcome recorded
Phase 1	NCT04697576	Oct 2021 → Sep 2027 expected	cutaneous melanoma, metastatic melanoma	Carlo Contreras	Recruiting	No outcome recorded
Phase 1	NCT03735277	Mar 2021 → Jul 2022	ischemic stroke	BHI Therapeutic Sciences	Unknown	No outcome recorded
Phase 1	NCT04687657	Feb 2021 → Feb 2024	acute myelomonocytic leukemia M4	First Affiliated Hospital Xi'an Jiaotong University	Unknown	No outcome recorded
Phase 1	NCT03888989	Sep 2019 → Dec 2023	influenza	Stanford University	Terminated	No outcome recorded
Phase 1	NCT03945825	Jun 2019 → Sep 2020	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT03352310	Apr 2018 → Jun 2020	brain hypoxia - ischemia, neonatal anemia	Mononuclear Therapeutics Ltd.	Unknown	No outcome recorded
Phase 1	NCT02998736	Nov 2017 → Sep 2022	digestive system cancer	Ottawa Hospital Research Institute	Completed	No outcome recorded
Phase 1	NCT03312699	Sep 2017 → Dec 2023	hepatitis A virus infection, influenza, typhoid fever	Stanford University	Completed	No outcome recorded
Phase 1	NCT02665871	Mar → Jun 2016	influenza	Beijing Chaoyang District Centre for Disease Control and Prevention	Unknown	No outcome recorded
Phase 1	NCT02397018	May 2015 → Feb 2017	ischemic stroke	Joanne Kurtzberg, MD	Completed	No outcome recorded
Phase 1	NCT02267733	Oct 2014 → Dec 2015	influenza, monoclonal gammopathy	Yale University	Completed	No outcome recorded
Phase 1	NCT03453801	Sep 2014 → Jan 2019	influenza	Stanford University	Completed	No outcome recorded
Phase 1	NCT01941758	Nov 2013 → Nov 2014	central nervous system neoplasm	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 1	NCT01695733	Sep 2011 → Sep 2013	neoplasm	Washington University School of Medicine	Terminated	No outcome recorded
Phase 1	NCT01525004	Sep 2011 → Jun 2012	disease related to solid organ transplantation	Vanderbilt University	Completed	No outcome recorded
Phase 1	NCT01302990	Feb → Jul 2011	influenza	Medicago	Completed	No outcome recorded
Phase 1	NCT01164553	Oct 2010 → Oct 2012	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT01216332	Oct 2010 → May 2013	childhood acute lymphoblastic leukemia	Vanderbilt University	Completed	No outcome recorded
Phase 1	NCT01059617	Feb 2010 → Jan 2011	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00662272	Jun → Oct 2008	influenza	Colby Pharmaceutical Company	Completed	No outcome recorded
Phase 1	NCT00318058	Oct → Nov 2005	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00231907	Sep 2005 → Mar 2007	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00231920	Oct 2004 → Aug 2006	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 1/210 trials
Phase 1/2	NCT05794425	Aug 2023 → Apr 2025	bone marrow failure syndrome	Shandong Qilu Stem Cells Engineering Co., Ltd.	Unknown	No outcome recorded
Phase 1/2	NCT04013646	May 2019 → Nov 2020	stroke disorder	Bundang CHA Hospital	Unknown	No outcome recorded
Phase 1/2	NCT03913312	Sep 2018 → Dec 2019	acute myeloid leukemia	Ruijin Hospital	Unknown	No outcome recorded
Phase 1/2	NCT03473301	Apr 2018 → Feb 2020	cerebral palsy	Joanne Kurtzberg, MD	Completed	No outcome recorded
Phase 1/2	NCT02668315	Dec 2015 → Aug 2018	hematopoietic and lymphoid cell neoplasm	Maisonneuve-Rosemont Hospital	Completed	No outcome recorded
Phase 1/2	NCT02336984	Jun 2014 → Apr 2016	breast cancer	H. Lee Moffitt Cancer Center and Research Institute	Withdrawn	No outcome recorded
Phase 1/2	NCT02127892	Jan 2007 → Aug 2016	severe combined immunodeficiency	Neena Kapoor, M.D.	Terminated	No outcome recorded
Phase 1/2	NCT00386542	Oct 2006 → Nov 2009	influenza	Pedro Moro	Completed	No outcome recorded
Phase 1/2	NCT00336453	Oct 2006 → Jul 2007	influenza	Protein Sciences Corporation	Completed	No outcome recorded
Phase 1/2	NCT00091702	? → Jan 2006	HIV infectious disease, influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 268 trials
Phase 2	NCT07524530	Jul 2026 → Jun 2033 expected	core binding factor acute myeloid leukemia, lymphoma	National Cancer Institute (NCI)	Not yet recruiting	No outcome recorded
Phase 2	NCT07192458	Sep 2025 → Dec 2028 expected	influenza	Vanderbilt University Medical Center	Recruiting	No outcome recorded
Phase 2	NCT06040476	Sep 2025 → Dec 2027 expected	ischemic stroke	StemCyte, Inc.	Not yet recruiting	No outcome recorded
Phase 2	NCT05947071	Sep 2024 → Jul 2027 expected	disease related to solid organ transplantation, influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Recruiting	No outcome recorded
Phase 2	NCT06431607	May → Dec 2024	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT05291676	Nov 2023 → Apr 2027 expected	influenza	Yale University	Recruiting	No outcome recorded
Phase 2	NCT05909423	Sep 2023 → Sep 2025 overdue	colorectal cancer	Zealand University Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT05519839	Dec 2022 → Jul 2023	COVID-19, influenza	Novavax	Completed	No outcome recorded
Phase 2	NCT05215327	Nov 2022 → Jul 2027 expected	disease related to solid organ transplantation, influenza	Vanderbilt University Medical Center	Recruiting	No outcome recorded
Phase 2	NCT05294588	Apr 2022 → Feb 2026	gonorrhea	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 2	NCT05116917	Nov 2021 → Oct 2023	malignant pancreatic neoplasm	Herlev Hospital	Terminated	No outcome recorded
Phase 2	NCT05325632	Oct 2021 → Feb 2027 expected	HER2 positive breast carcinoma	H. Lee Moffitt Cancer Center and Research Institute	Recruiting	No outcome recorded
Phase 2	NCT04613206	Jan 2021 → Jul 2026 overdue	disease related to solid organ transplantation, influenza	Vanderbilt University Medical Center	Active not recruiting	No outcome recorded
Phase 2	NCT02434965	Dec 2019 → Jan 2021	brain hypoxia - ischemia	New York Medical College	Withdrawn	No outcome recorded
Phase 2	NCT03630809	Jan 2019 → Apr 2022	HER2 positive breast carcinoma, female breast carcinoma, male breast carcinoma	H. Lee Moffitt Cancer Center and Research Institute	Terminated	No outcome recorded
Phase 2	NCT03658629	Sep 2018 → Apr 2019	influenza	Novavax	Terminated	No outcome recorded
Phase 2	NCT03339713	Dec 2017 → Jul 2018	—	Janssen Vaccines & Prevention B.V.	Completed	No outcome recorded
Phase 2	NCT03277703	Nov 2017 → Jan 2020	inflammatory bowel disease, rheumatic disorder, type III hypersensitivity disease	Stony Brook University	Completed	No outcome recorded
Phase 2	NCT03179761	Oct 2017 → Feb 2022	disease related to hematopoietic stem cell transplant	Vanderbilt-Ingram Cancer Center	Completed	No outcome recorded
Phase 2	NCT03004976	Mar 2017 → Jul 2020	brain injury, ischemic stroke	Joanne Kurtzberg, MD	Completed	No outcome recorded
Phase 2	NCT03016143	Oct → Nov 2016	influenza	Research Institute for Biological Safety Problems	Completed	No outcome recorded
Phase 2	NCT02847182	Sep 2016 → Aug 2018	autism, autism spectrum disorder 1	Joanne Kurtzberg, MD	Completed	No outcome recorded
Phase 2	NCT02860039	Sep 2016 → Dec 2021	cancer, disease related to hematopoietic stem cell transplant, influenza	Vanderbilt-Ingram Cancer Center	Completed	No outcome recorded
Phase 2	NCT02518555	Jan 2016 → Dec 2025	chronic lymphocytic leukemia/small lymphocytic lymphoma	Jennifer Woyach	Completed	No outcome recorded
Phase 2	NCT01924169	Nov 2014 → Feb 2017	hematologic disorder	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 2	NCT01896869	Nov 2013 → May 2019	pancreatic adenocarcinoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
Phase 2	NCT01819155	Apr → Sep 2013	influenza	PATH	Completed	No outcome recorded
Phase 2	NCT01763099	Jan 2013 → Jan 2015	disease related to hematopoietic stem cell transplant, hematologic disorder	Nanfang Hospital, Southern Medical University	Unknown	No outcome recorded
Phase 2	NCT01666782	Aug 2012 → Jun 2015	cancer, influenza	Saad Jamshed MD	Completed	No outcome recorded
Phase 2	NCT01408563	Dec 2011 → Jun 2017	Hodgkins lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, plasma cell myeloma	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT01436370	Oct 2011 → Feb 2013	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT01181323	Sep 2011 → May 2013	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT01403376	Sep 2011 → Jan 2012	multiple sclerosis	Sanofi	Completed	No outcome recorded
Phase 2	NCT01328496	Jun 2011 → Oct 2016	disease related to transplantation, hematopoietic and lymphoid cell neoplasm	St. Jude Children's Research Hospital	Completed	No outcome recorded
Phase 2	NCT01258595	Nov 2010 → Mar 2011	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 2	NCT01173211	Sep 2010 → Nov 2011	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00968890	Sep 2009 → Sep 2010	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00956046	Sep 2009 → Jan 2011	swine influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 2	NCT01011049	Sep 2009 → May 2010	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 2	NCT00936468	Sep 2009 → Jun 2010	influenza	Colby Pharmaceutical Company	Completed	No outcome recorded
Phase 2	NCT01072734	Sep 2009 → Jan 2010	systemic lupus erythematosus	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT00943202	Aug 2009 → May 2010	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00956202	Aug 2009 → Sep 2010	swine influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 2	NCT00943878	Aug 2009 → Apr 2010	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00905125	Jun 2009 → Mar 2010	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00918268	Jun → Jul 2009	influenza	Novartis Vaccines	Completed	No outcome recorded
Phase 2	NCT00741039	Aug 2008 → Aug 2012	breast cancer, lung cancer, prostate cancer	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 2	NCT00604201	May 2008 → Oct 2016	aplastic anemia, myelodysplastic syndrome	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2	NCT00623181	Jan → May 2008	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 2	NCT00596336	Oct 2007 → Dec 2011	chronic lymphocytic leukemia/small lymphocytic lymphoma	The Royal Bournemouth Hospital	Terminated	No outcome recorded
Phase 2	NCT00776438	Sep 2007 → Feb 2009	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 2	NCT00504231	Sep 2007 → Jan 2008	influenza	PATH	Completed	No outcome recorded
Phase 2	NCT00491257	Jun → Jul 2007	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 2	NCT00408395	Nov 2006 → Aug 2007	influenza	Novartis Vaccines	Completed	No outcome recorded
Phase 2	NCT00386113	Oct → Nov 2006	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00386698	Oct → Dec 2006	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00391391	Oct 2006 → Mar 2007	influenza	Sanofi	Completed	No outcome recorded
Phase 2	NCT00377585	Sep 2006 → Jan 2007	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00296829	Jan 2006 → Feb 2007	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 2	NCT00318149	Oct 2005 → May 2006	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00258934	Sep 2005 → Jun 2008	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 2	NCT00170547	Sep 2005 → Jan 2006	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00676806	Jul 2005 → Jul 2013	aplastic anemia, leukemia, plasma cell myeloma	Tufts Medical Center	Terminated	No outcome recorded
Phase 2	NCT00316628	Jun 2005 → ?	influenza	Novartis	Completed	No outcome recorded
Phase 2	NCT00316615	Jun 2005 → ?	influenza	Novartis	Completed	No outcome recorded
Phase 2	NCT00115531	Apr → Nov 2005	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00283283	Nov 2004	influenza	U.S. Army Medical Research and Development Command	Completed	No outcome recorded
Phase 2	NCT00006146	Aug → Sep 2000	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 2/37 trials
Phase 2/3	NCT03699839	Oct 2018 → Aug 2020	disease related to solid organ transplantation, influenza	Oriol Manuel	Completed	No outcome recorded
Phase 2/3	NCT03666806	Aug 2018 → Sep 2019	sickle cell disease	Makerere University	Unknown	No outcome recorded
Phase 2/3	NCT02093260	May → Jul 2014	—	PT Bio Farma	Completed	No outcome recorded
Phase 2/3	NCT00607178	Jan → Sep 2008	coronary artery disorder, myocardial infarction	Shahid Beheshti University of Medical Sciences	Completed	No outcome recorded
Phase 2/3	NCT00607217	Jan → Sep 2008	intermediate coronary syndrome, myocardial infarction	Shahid Beheshti University of Medical Sciences	Completed	No outcome recorded
Phase 2/3	NCT00242424	Sep 2005 → Sep 2006	—	Seattle Children's Hospital	Completed	No outcome recorded
Phase 2/3	NCT00371098	Oct 2004 → Dec 2005	coronary artery disorder	National Institute of Cardiology, Warsaw, Poland	Completed	No outcome recorded
Phase 344 trials
Phase 3	NCT06291857	Dec 2024 → Dec 2025	COVID-19	Novavax	Completed	No outcome recorded
Phase 3	NCT06279871	Mar → Oct 2024	COVID-19	Arcturus Therapeutics, Inc.	Completed	No outcome recorded
Phase 3	NCT06060457	Sep 2023 → Jun 2024	respiratory syncytial virus infectious disease	ModernaTX, Inc.	Completed	No outcome recorded
Phase 3	NCT05669079	Aug 2023 → Aug 2026 overdue	—	The First Affiliated Hospital of Soochow University	Not yet recruiting	No outcome recorded
Phase 3	NCT05479370	Sep 2022 → Apr 2023	—	Tan Tock Seng Hospital	Completed	No outcome recorded
Phase 3	NCT05091307	Nov 2021 → Jun 2022	—	Janssen Vaccines & Prevention B.V.	Completed	No outcome recorded
Phase 3	NCT04024228	Oct 2019 → Jan 2020	—	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT03572491	Sep 2017 → May 2018	influenza	Research Institute for Biological Safety Problems	Completed	No outcome recorded
Phase 3	NCT02545868	Oct 2015 → Feb 2017	relapsing-remitting multiple sclerosis	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT02519855	Sep 2015 → Jan 2016	herpes zoster	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT02381418	Mar 2015	influenza	Abbott	Completed	No outcome recorded
Phase 3	NCT01761435	Oct 2012 → Jan 2014	disease related to solid organ transplantation	Fundación Pública Andaluza Progreso y Salud	Completed	No outcome recorded
Phase 3	NCT01527825	Sep 2012 → Jun 2014	influenza	University of Witwatersrand, South Africa	Completed	No outcome recorded
Phase 3	NCT01633749	Jul 2012	—	Abbott Biologicals	Completed	No outcome recorded
Phase 3	NCT01551823	Mar → May 2012	influenza	Institute of Medical Biology, Chinese Academy of Medical Sciences	Completed	No outcome recorded
Phase 3	NCT01551810	Mar → May 2012	influenza	Institute of Medical Biology, Chinese Academy of Medical Sciences	Completed	No outcome recorded
Phase 3	NCT01034254	Nov 2010 → May 2014	influenza	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 3	NCT01249183	Oct 2010 → Sep 2011	diphtheria, pertussis, poliomyelitis, tetanus	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT01319955	Aug 2010 → Apr 2017	influenza, pneumonia	International Centre for Diarrhoeal Disease Research, Bangladesh	Completed	No outcome recorded
Phase 3	NCT01144299	Jun → Jul 2010	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01146015	Jun → Jul 2010	influenza	Abbott Biologicals	Completed	No outcome recorded
Phase 3	NCT00999206	Jan → Aug 2010	influenza	Abbott Biologicals	Completed	No outcome recorded
Phase 3	NCT00971425	Sep → Nov 2009	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01022749	Sep 2009 → Jul 2011	inflammatory bowel disease	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT00920374	Jun → Jul 2009	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00881842	Jun → Jul 2009	influenza	Abbott Biologicals	Completed	No outcome recorded
Phase 3	NCT00706563	Jul 2008	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00665509	Jun → Jul 2008	influenza	Solvay Biologicals	Completed	No outcome recorded
Phase 3	NCT00617851	Nov → Dec 2007	influenza	Novartis Vaccines	Completed	No outcome recorded
Phase 3	NCT00521586	Sep 2007 → Dec 2013	influenza	Pfizer	Completed	No outcome recorded
Phase 3	NCT00479921	Jun 2007 → ?	—	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00476307	Jun → Jul 2007	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00453986	Apr → Nov 2007	meningococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00391053	Oct 2006 → Jul 2007	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT00395174	Oct 2006 → May 2007	influenza	Protein Sciences Corporation	Completed	No outcome recorded
Phase 3	NCT00380211	Sep → Nov 2006	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00346723	Jul 2006 → ?	—	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00345904	Jul → Aug 2006	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00325260	Mar 2006 → ?	—	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00232947	Oct 2005 → Feb 2006	influenza	ID Biomedical Corporation, Quebec	Completed	No outcome recorded
Phase 3	NCT00197288	Oct 2005 → May 2006	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00197223	Sep → Oct 2005	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00700193	Mar 2005 → Jun 2006	influenza	Seqirus	Completed	No outcome recorded
Phase 3	NCT00100399	Dec 2004	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 4107 trials
Phase 4	NCT07617376	Nov 2025 → Dec 2026 expected	cardiac rhythm disease, heart failure, myocardial infarction, pulmonary embolism	Wroclaw Medical University	Recruiting	No outcome recorded
Phase 4	NCT07493460	Aug 2025 → Oct 2026 expected	immunodeficiency disease	Washington University School of Medicine	Active not recruiting	No outcome recorded
Phase 4	NCT06503900	Sep 2024 → Aug 2025	—	Duke University	Completed	No outcome recorded
Phase 4	NCT06518577	Sep → Dec 2024	influenza	Duke University	Completed	No outcome recorded
Phase 4	NCT06567860	May 2024 → Feb 2025	influenza	La Jolla Institute for Immunology	Completed	No outcome recorded
Phase 4	NCT05616546	Oct 2023 → Dec 2029 expected	influenza	Emory University	Recruiting	No outcome recorded
Phase 4	NCT06091410	Sep 2023 → Feb 2025	COVID-19, influenza	Catholic Kwandong University	Unknown	No outcome recorded
Phase 4	NCT05801978	Apr 2023 → Sep 2027 expected	—	Emory University	Recruiting	No outcome recorded
Phase 4	NCT05654441	Oct 2022 → Dec 2023	—	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 4	NCT05170399	Sep 2022 → Aug 2026 overdue	lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	Recruiting	No outcome recorded
Phase 4	NCT05480436	Aug 2022 → Jan 2023	COVID-19, hemolytic anemia	China National Biotec Group Company Limited	Unknown	No outcome recorded
Phase 4	NCT05298800	Oct 2021 → Dec 2022	—	Centers for Disease Control and Prevention, China	Unknown	No outcome recorded
Phase 4	NCT05028361	Oct 2021 → Mar 2023	—	Duke University	Completed	No outcome recorded
Phase 4	NCT05144464	Sep → Nov 2021	influenza	Jiangsu Province Centers for Disease Control and Prevention	Unknown	No outcome recorded
Phase 4	NCT05050318	Sep → Nov 2021	—	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT05079152	May 2021	influenza, streptococcal pneumonia	China National Biotec Group Company Limited	Unknown	No outcome recorded
Phase 4	NCT04998344	Apr 2021 → Dec 2024	influenza	University of Bergen	Unknown	No outcome recorded
Phase 4	NCT04790851	Mar → Sep 2021	COVID-19, influenza, streptococcal pneumonia	China National Biotec Group Company Limited	Completed	No outcome recorded
Phase 4	NCT05070494	Mar 2021 → Apr 2022	end stage renal failure	Mahidol University	Unknown	No outcome recorded
Phase 4	NCT06252051	Jan 2021 → Mar 2022	chronic kidney disease, diabetes mellitus, influenza	Padjadjaran University	Completed	No outcome recorded
Phase 4	NCT04304768	Nov 2020 → Jan 2027 expected	immunodeficiency disease	University of Miami	Active not recruiting	No outcome recorded
Phase 4	NCT04487041	Oct 2020 → Apr 2027 expected	influenza	University of Miami	Active not recruiting	No outcome recorded
Phase 4	NCT06286488	Sep 2020 → Aug 2023	influenza, obesity disorder	Medical University of Warsaw	Unknown	No outcome recorded
Phase 4	NCT04559204	Sep → Nov 2020	influenza, streptococcal pneumonia	China National Biotec Group Company Limited	Completed	No outcome recorded
Phase 4	NCT04080531	Oct 2019 → May 2021	plasma cell neoplasm	Emory University	Completed	No outcome recorded
Phase 4	NCT04091880	Sep 2019 → Jan 2020	enterovirus infectious disease, influenza	China National Biotec Group Company Limited	Completed	No outcome recorded
Phase 4	NCT03756246	Jun 2019 → May 2020	depressive disorder	University of Texas at Austin	Unknown	No outcome recorded
Phase 4	NCT03898973	Apr 2019 → Nov 2023	influenza	Stanford University	Withdrawn	No outcome recorded
Phase 4	NCT03315975	Oct 2017 → Jul 2026 overdue	viral infectious disease	University of Pennsylvania	Active not recruiting	No outcome recorded
Phase 4	NCT03330132	Oct 2017 → Dec 2025	influenza	The University of Hong Kong	Completed	No outcome recorded
Phase 4	NCT02868970	Feb 2017 → Jul 2021	—	Canadian Immunization Research Network	Completed	No outcome recorded
Phase 4	NCT02838992	Feb 2017 → Dec 2018	aplastic anemia	Jinan Military General Hospital	Unknown	No outcome recorded
Phase 4	NCT02947217	Jan 2017 → Dec 2023	infertility disorder	Center for Human Reproduction	Unknown	No outcome recorded
Phase 4	NCT02946177	Jan 2017 → Dec 2020	habitual spontaneous abortion, infertility disorder	Center for Human Reproduction	Unknown	No outcome recorded
Phase 4	NCT02957890	Nov 2016 → Sep 2025 overdue	influenza	The University of Hong Kong	Active not recruiting	No outcome recorded
Phase 4	NCT02831608	Oct 2016 → Apr 2021	heart failure, influenza, myocardial infarction, stroke disorder	Ole Frobert, MD, PhD	Completed	No outcome recorded
Phase 4	NCT02908269	Sep → Dec 2016	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT02783170	Sep 2016 → Apr 2018	pregnancy disorder	Duke University	Completed	No outcome recorded
Phase 4	NCT02655874	May 2016 → Jun 2017	influenza	Tan Tock Seng Hospital	Completed	No outcome recorded
Phase 4	NCT02882100	Apr 2016 → Oct 2018	influenza	Insight Therapeutics, LLC	Completed	No outcome recorded
Phase 4	NCT02563093	Sep → Dec 2015	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT03023709	Sep → Dec 2015	influenza	Stanford University	Terminated	No outcome recorded
Phase 4	NCT02473510	Jun 2015 → Jan 2016	influenza	MedImmune LLC	Completed	No outcome recorded
Phase 4	NCT03028987	Nov 2014 → Nov 2015	influenza	Stanford University	Terminated	No outcome recorded
Phase 4	NCT02290691	Nov 2014 → Jan 2015	influenza	PharmaJet, Inc.	Completed	No outcome recorded
Phase 4	NCT03695432	Oct 2014 → Apr 2015	influenza	Indonesia University	Completed	No outcome recorded
Phase 4	NCT02263027	Oct 2014 → Jan 2016	influenza	Mount Sinai Hospital, Canada	Completed	No outcome recorded
Phase 4	NCT03028974	Sep 2014 → Nov 2017	influenza	Stanford University	Completed	No outcome recorded
Phase 4	NCT02311855	Aug 2014 → Dec 2015	rheumatoid arthritis	Bassett Healthcare	Completed	No outcome recorded
Phase 4	NCT01811823	Mar → Nov 2014	HIV infectious disease, influenza, tuberculosis	University of Witwatersrand, South Africa	Completed	No outcome recorded
Phase 4	NCT03266237	Dec 2013 → May 2016	influenza	National University Hospital, Singapore	Completed	No outcome recorded
Phase 4	NCT03020537	Oct → Dec 2013	influenza	Stanford University	Completed	No outcome recorded
Phase 4	NCT01946438	Sep → Dec 2013	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT01816464	Sep 2013 → Feb 2014	influenza	University of Witwatersrand, South Africa	Completed	No outcome recorded
Phase 4	NCT01812980	May → Jul 2013	HIV infectious disease, influenza	University of Witwatersrand, South Africa	Completed	No outcome recorded
Phase 4	NCT01863433	May → Jun 2013	influenza	Seqirus	Completed	No outcome recorded
Phase 4	NCT01859143	May → Dec 2013	influenza	MedImmune LLC	Completed	No outcome recorded
Phase 4	NCT03023553	Dec 2012 → Feb 2013	influenza	Stanford University	Completed	No outcome recorded
Phase 4	NCT02134184	Oct → Dec 2012	cytomegalovirus infection, influenza	Stanford University	Completed	No outcome recorded
Phase 4	NCT03022435	Oct 2012 → Jan 2013	influenza	Stanford University	Completed	No outcome recorded
Phase 4	NCT01691326	Sep → Dec 2012	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT01665807	Sep → Dec 2012	influenza	Brenda Coleman	Completed	No outcome recorded
Phase 4	NCT01644149	Jan → Feb 2012	—	PharmaJet, Inc.	Completed	No outcome recorded
Phase 4	NCT03022422	Sep → Dec 2011	influenza	Stanford University	Completed	No outcome recorded
Phase 4	NCT01422200	Aug → Dec 2011	Duchenne muscular dystrophy, congenital muscular dystrophy, spinal muscular atrophy	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 4	NCT02141581	Aug 2011 → Dec 2014	influenza	Stanford University	Completed	No outcome recorded
Phase 4	NCT01262846	Nov 2010 → Apr 2011	HIV infectious disease	University of Pennsylvania	Completed	No outcome recorded
Phase 4	NCT01196026	Sep 2010 → May 2011	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT03022396	Sep 2010 → Jan 2011	influenza	Stanford University	Completed	No outcome recorded
Phase 4	NCT01831934	Sep 2010 → Dec 2011	MELAS syndrome	Stanford University	Completed	No outcome recorded
Phase 4	NCT03020498	Sep 2010 → Dec 2011	influenza	Stanford University	Completed	No outcome recorded
Phase 4	NCT00987350	Jan → May 2010	—	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 4	NCT01002508	Nov 2009 → Mar 2010	scleroderma	Tel-Aviv Sourasky Medical Center	Unknown	No outcome recorded
Phase 4	NCT01000584	Nov 2009 → Feb 2010	swine influenza	David Scheifele	Completed	No outcome recorded
Phase 4	NCT01987349	Sep 2009 → Jan 2010	influenza	Stanford University	Completed	No outcome recorded
Phase 4	NCT02133781	Jul → Dec 2009	influenza	Stanford University	Completed	No outcome recorded
Phase 4	NCT00893906	May 2009 → Dec 2012	influenza	PATH	Completed	No outcome recorded
Phase 4	NCT01693380	May → Jun 2009	influenza	Butantan Institute	Completed	No outcome recorded
Phase 4	NCT00888381	May 2009	influenza	Seqirus	Completed	No outcome recorded
Phase 4	NCT00812110	Dec 2008 → Sep 2009	influenza	Akron Children's Hospital	Completed	No outcome recorded
Phase 4	NCT01119157	Nov 2008 → Mar 2009	—	National Centre for Epidemiology, Hungary	Unknown	No outcome recorded
Phase 4	NCT00961337	Oct 2008 → Mar 2009	influenza	Centers for Disease Control, Taiwan	Completed	No outcome recorded
Phase 4	NCT00877396	Sep 2008 → May 2011	influenza	McMaster University	Completed	No outcome recorded
Phase 4	NCT00755274	Sep 2008 → Jan 2009	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT00743275	Aug → Nov 2008	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT01827462	Oct 2007 → Dec 2015	influenza	Stanford University	Completed	No outcome recorded
Phase 4	NCT00561002	Oct 2007 → May 2008	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT00442975	Mar → Sep 2007	influenza	Public Health England	Completed	No outcome recorded
Phase 4	NCT00377611	Oct 2006 → Jun 2007	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00390884	Oct 2006 → Jun 2007	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT00389532	Oct 2006 → Apr 2008	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT00402805	Oct 2006 → Feb 2007	bronchiolitis obliterans syndrome	University Health Network, Toronto	Completed	No outcome recorded
Phase 4	NCT00389857	Oct 2006 → Sep 2007	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT00363870	Sep 2006 → Jun 2007	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00258817	Oct 2005 → Mar 2006	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT00258830	Sep 2005 → Feb 2006	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT00138385	Aug 2005 → Jun 2007	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 4	NCT00133510	Nov 2004 → Sep 2006	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 4	NCT00133523	Oct 2004 → Jul 2007	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 4	NCT00222638	Oct 2004 → May 2005	—	University Of Perugia	Completed	No outcome recorded
Phase 4	NCT00831675	Sep 2004 → Apr 2006	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT00831987	Aug 2004 → Feb 2006	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT00161122	Sep 2003 → Jun 2006	respiratory tract infectious disorder	UMC Utrecht	Completed	No outcome recorded
Phase 4	NCT00836953	Sep 2003 → Jan 2004	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT00835926	Jul → Sep 2003	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT00138294	Oct 1998 → Jun 2010	influenza	Baylor College of Medicine	Completed	No outcome recorded
Phase 4	NCT00138281	? → Nov 2005	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase not applicable31 trials
—	NCT07259252	Dec 2025 → Mar 2029 expected	acute coronary syndrome	Tongji Hospital	Recruiting	No outcome recorded
—	NCT07201233	Nov 2025 → Nov 2027 expected	bone marrow disorder	Shandong Qilu Stem Cells Engineering Co., Ltd.	Not yet recruiting	No outcome recorded
—	NCT05663463	Sep 2023 → Jun 2025	disease related to solid organ transplantation	University of Minnesota	Completed	No outcome recorded
—	NCT02707692	Aug 2016 → Apr 2020	AIDS	University of California, San Diego	Completed	No outcome recorded
—	NCT02653495	Jan 2016 → Mar 2017	immunodeficiency disease, metabolic syndrome X	Rockefeller University	Terminated	No outcome recorded
—	NCT02559505	Oct 2015 → Jul 2020	influenza	University of Rochester	Completed	No outcome recorded
—	NCT02415166	Jul 2015 → Mar 2016	major depressive disorder	Laureate Institute for Brain Research, Inc.	Terminated	No outcome recorded
—	NCT02154061	Apr 2015 → May 2017	influenza	Emory University	Completed	No outcome recorded
—	NCT01451528	Jul 2014 → Dec 2015	traumatic brain injury	Bundang CHA Hospital	Withdrawn	No outcome recorded
—	NCT01916759	Jun → Dec 2013	AIDS, influenza	Emory University	Completed	No outcome recorded
—	NCT01666535	Sep 2012 → Mar 2013	inflammatory bowel disease	University of Calgary	Completed	No outcome recorded
—	NCT01601158	May 2012 → Aug 2013	global developmental delay with or without impaired intellectual development	MinYoung Kim, M.D.	Completed	No outcome recorded
—	NCT01465477	Nov 2011 → Jun 2012	fibromyalgia	Tel-Aviv Sourasky Medical Center	Unknown	No outcome recorded
—	NCT01561989	Oct 2011 → Jul 2013	—	Roswell Park Cancer Institute	Terminated	No outcome recorded
—	NCT01733056	Jan 2011 → Jan 2013	immunodeficiency disease	Emory University	Completed	No outcome recorded
—	NCT01264601	Oct 2010 → May 2012	food allergy	University of Michigan	Completed	No outcome recorded
—	NCT01180699	Oct 2010 → Aug 2012	—	University of Alberta	Completed	No outcome recorded
—	NCT01232868	Oct 2010 → Oct 2011	influenza	Emory University	Completed	No outcome recorded
—	NCT01193660	May 2010 → Apr 2011	cerebral palsy	Sung Kwang Medical Foundation	Completed	No outcome recorded
—	NCT01044095	Nov 2009 → Jul 2010	influenza	Armed Forces Research Institute of Medical Sciences, Thailand	Completed	No outcome recorded
—	NCT01000246	Oct → Dec 2009	breast carcinoma, heart failure	St. Antonius Hospital	Completed	No outcome recorded
—	NCT01768845	Feb 2009 → May 2019	B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, acute myeloid leukemia, aplastic anemia +3	West Virginia University	Completed	No outcome recorded
—	NCT00758212	Nov 2008 → Jan 2009	AIDS, influenza	Hadassah Medical Organization	Unknown	No outcome recorded
—	NCT00822627	Nov 2007 → Apr 2008	influenza	University of Arizona	Completed	No outcome recorded
—	NCT00558649	May → Sep 2007	influenza	NanoPass Technologies Ltd	Completed	No outcome recorded
—	NCT00466037	Sep 2005 → Feb 2006	rheumatoid arthritis	Tel-Aviv Sourasky Medical Center	Terminated	No outcome recorded
—	NCT00170508	Jun → Aug 2005	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00214071	Oct 2004 → Jun 2006	obstructive sleep apnea syndrome	University of Wisconsin, Madison	Completed	No outcome recorded
—	NCT00158665	Aug → Dec 2004	influenza	Kaiser Permanente	Completed	No outcome recorded
—	NCT00022035	Aug 2000 → Nov 2002	infectious disease, leukemia	Roswell Park Cancer Institute	Completed	No outcome recorded
—	NCT00001080	—	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded

Phase not stated1 trial
—	NCT03327467	—	apraxia, brain hypoxia - ischemia, cerebral palsy, hydrocephalus	Joanne Kurtzberg, MD	Available	No outcome recorded

Also used as a comparator or background therapy in 181 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT06067555 Comparator	Jan 2024 → May 2026 overdue	vaccinia	Yale University	Recruiting	No outcome recorded
Phase 0	NCT01967238 Comparator	Mar 2013 → Mar 2023	—	Rockefeller University	Terminated	No outcome recorded
Phase 0	NCT01385215 Comparator	Apr → Jun 2011	—	John Sundy	Completed	No outcome recorded
Phase 119 trials
Phase 1	NCT06602531 Comparator	Dec 2024 → Jun 2025	influenza	Arcturus Therapeutics, Inc.	Completed	No outcome recorded
Phase 1	NCT03996538 Background	Jun 2019 → Feb 2020	immunodeficiency disease	UConn Health	Completed	No outcome recorded
Phase 1	NCT03109600 Comparator	Apr → Sep 2017	—	PT Bio Farma	Completed	No outcome recorded
Phase 1	NCT03926416 Comparator	Feb 2017 → May 2018	influenza	Codagenix, Inc	Completed	No outcome recorded
Phase 1	NCT02645032 Comparator	May 2016 → Feb 2017	typhoid fever	International Vaccine Institute	Completed	No outcome recorded
Phase 1	NCT03028116 Comparator	May → Jun 2016	influenza	Research Institute for Biological Safety Problems	Completed	No outcome recorded
Phase 1	NCT02500680 Comparator	Jul 2015 → Dec 2020	influenza	Nova Immunotherapeutics Limited	Unknown	No outcome recorded
Phase 1	NCT02330003 Comparator	May → Aug 2013	—	Il-Yang Pharm. Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT01488188 Comparator	Dec 2011 → May 2013	—	International Vaccine Institute	Completed	No outcome recorded
Phase 1	NCT01354379 Comparator	May 2011 → Jun 2012	—	NanoBio Corporation	Completed	No outcome recorded
Phase 1	NCT01215734 Comparator	Oct 2010 → Apr 2012	disease related to hematopoietic stem cell transplant	Vanderbilt-Ingram Cancer Center	Completed	No outcome recorded
Phase 1	NCT02050971 Comparator	Oct 2010 → Dec 2014	bronchopulmonary dysplasia, cerebrovascular disorder, necrotizing enterocolitis, neonatal anemia +2	Pomeranian Medical University Szczecin	Unknown	No outcome recorded
Phase 1	NCT01096056 Background	Apr → Dec 2010	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00858611 Background	Mar 2009 → Jun 2010	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00868218 Comparator	Mar 2009 → Jul 2010	influenza	Rebecca Cox	Completed	No outcome recorded
Phase 1	NCT00848848 Comparator	Oct 2008 → Apr 2009	influenza	Seqirus	Completed	No outcome recorded
Phase 1	NCT00906750 Comparator	Oct 2008 → Jul 2011	cancer	St. Jude Children's Research Hospital	Completed	No outcome recorded
Phase 1	NCT00693706 Comparator	Jun 2008 → Mar 2009	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00735020 Comparator	Jun → Aug 2008	influenza	Novartis Vaccines	Completed	No outcome recorded

Phase 1/210 trials
Phase 1/2	NCT06382311 Comparator	Apr 2024 → Jan 2026	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 1/2	NCT03293498 Comparator	Sep 2017 → Mar 2018	influenza	Novavax	Completed	No outcome recorded
Phase 1/2	NCT02263040 Comparator	Oct 2014 → Jul 2016	influenza	Mount Sinai Hospital, Canada	Completed	No outcome recorded
Phase 1/2	NCT02249221 Comparator	Oct → Nov 2014	influenza	Green Cross Corporation	Completed	No outcome recorded
Phase 1/2	NCT02121782 Comparator	May → Jun 2014	influenza	Green Cross Corporation	Completed	No outcome recorded
Phase 1/2	NCT01707602 Comparator	Oct → Dec 2012	influenza	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 1/2	NCT01248208 Comparator	Sep 2010 → Sep 2011	food allergy	Walter Reed Army Medical Center	Completed	No outcome recorded
Phase 1/2	NCT01224262 Background	Sep 2010 → Dec 2011	influenza	Liquidia Technologies, Inc.	Completed	No outcome recorded
Phase 1/2	NCT01010737 Background	Sep 2009 → Mar 2010	influenza	BiondVax Pharmaceuticals ltd.	Completed	No outcome recorded
Phase 1/2	NCT00305344 Comparator	Apr 2005 → May 2011	type 1 diabetes mellitus	University of Florida	Completed	No outcome recorded

Phase 239 trials
Phase 2	NCT07587801 Background	May → Jul 2026 overdue	—	Central Adelaide Local Health Network Incorporated	Not yet recruiting	No outcome recorded
Phase 2	NCT05606965 Comparator	Nov 2022 → Nov 2025	influenza	ModernaTX, Inc.	Completed	No outcome recorded
Phase 2	NCT05074303 Background	Jul 2022 → Mar 2024	—	University of Florida	Completed	No outcome recorded
Phase 2	NCT04176133 Background	Oct 2019 → Mar 2022	—	Robert J. Pignolo	Completed	No outcome recorded
Phase 2	NCT03336593 Comparator	Nov 2017 → Mar 2018	—	PT Bio Farma	Completed	No outcome recorded
Phase 2	NCT02918006 Comparator	Aug 2016 → Aug 2017	influenza	Vaxart	Completed	No outcome recorded
Phase 2	NCT02831751 Comparator	Apr → Jul 2016	primary viral infectious disease, respiratory tract infectious disorder	Medicago	Completed	No outcome recorded
Phase 2	NCT02649192 Comparator	Jan 2016 → Jun 2018	—	St. Jude Children's Research Hospital	Completed	No outcome recorded
Phase 2	NCT02553343 Comparator	Sep 2015 → Apr 2016	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 2	NCT02434276 Comparator	May → Aug 2015	influenza	VaxInnate Corporation	Unknown	No outcome recorded
Phase 2	NCT01974895 Comparator	Oct 2013 → Feb 2014	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01685372 Comparator	Sep 2012 → Sep 2015	HIV infectious disease, disease related to solid organ transplantation, rheumatic disorder	University of Colorado, Denver	Completed	No outcome recorded
Phase 2	NCT01622556 Background	Jan 2012 → Feb 2014	hematopoietic and lymphoid system neoplasm	University of Virginia	Terminated	No outcome recorded
Phase 2	NCT01195779 Comparator	Sep 2010 → Mar 2011	influenza	GlaxoSmithKline	Terminated	No outcome recorded
Phase 2	NCT01013675 Comparator	Nov 2009 → Apr 2011	—	Abbott Biologicals	Completed	No outcome recorded
Phase 2	NCT00985790 Comparator	Oct 2009 → May 2010	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00988143 Comparator	Oct → Dec 2009	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 2	NCT00915187 Comparator	Oct → Dec 2009	influenza	NasVax Ltd	Completed	No outcome recorded
Phase 2	NCT00880893 Comparator	Apr 2009 → Oct 2014	Dengue hemorrhagic fever	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 2	NCT00778895 Comparator	Nov 2008 → Aug 2009	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00538473 Comparator	Oct → Dec 2007	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00538213 Comparator	Oct → Nov 2007	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00545025 Comparator	Oct → Dec 2007	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00540592 Comparator	Oct 2007 → Jun 2008	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00540228 Comparator	Oct 2007 → May 2008	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00551031 Comparator	Oct 2007 → Jun 2008	influenza	Sanofi	Completed	No outcome recorded
Phase 2	NCT00532298 Comparator	Sep → Nov 2007	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00502593 Comparator	Jul 2007 → Dec 2009	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00478816 Comparator	May 2007 → Feb 2009	avian influenza	Novartis Vaccines	Completed	No outcome recorded
Phase 2	NCT00397215 Background	Nov 2006 → Sep 2009	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00374842 Comparator	Oct → Nov 2006	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00363077 Comparator	Oct → Nov 2006	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00388583 Comparator	Sep 2006 → Jun 2007	influenza	Sanofi	Completed	No outcome recorded
Phase 2	NCT00321373 Comparator	May → Jul 2006	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00321763 Comparator	Apr → Jul 2006	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00253734 Comparator	Nov 2005 → Oct 2006	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00307177 Comparator	Aug 2004 → Apr 2005	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00703651 Comparator	Sep 2003 → May 2006	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 2	NCT00766285 Comparator	? → Sep 2010	influenza	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded

Phase 2/32 trials
Phase 2/3	NCT01306682 Comparator	Mar 2011 → Jun 2012	influenza	University of Witwatersrand, South Africa	Completed	No outcome recorded
Phase 2/3	NCT01273974 Comparator	Oct → Nov 2009	—	Shiraz University of Medical Sciences	Completed	No outcome recorded
Phase 346 trials
Phase 3	NCT07604103 Comparator	Jan → Aug 2026 overdue	acute coronary syndrome, chronic obstructive pulmonary disease, pneumonia	University of Brawijaya	Recruiting	No outcome recorded
Phase 3	NCT06602024 Comparator	Sep 2024 → Aug 2025	influenza	ModernaTX, Inc.	Completed	No outcome recorded
Phase 3	NCT06097273 Comparator	Oct 2023 → May 2024	Orthocoronavirinae infectious disease, influenza	ModernaTX, Inc.	Completed	No outcome recorded
Phase 3	NCT05827978 Comparator	Apr 2023 → Jun 2024	influenza	ModernaTX, Inc.	Completed	No outcome recorded
Phase 3	NCT05705440 Background	Feb 2023 → Jan 2025	respiratory syncytial virus infectious disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT05568797 Background	Oct 2022 → Feb 2023	respiratory syncytial virus infectious disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT05144945 Comparator	Dec 2021 → Sep 2022	—	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT05470582 Comparator	Feb → Oct 2021	influenza	St. Petersburg Research Institute of Vaccines and Sera	Completed	No outcome recorded
Phase 3	NCT04526574 Comparator	Sep 2020 → Jun 2021	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT04143451 Comparator	Oct 2019 → Sep 2022	influenza	The University of Hong Kong	Unknown	No outcome recorded
Phase 3	NCT04120194 Comparator	Oct 2019 → Oct 2020	influenza	Novavax	Completed	No outcome recorded
Phase 3	NCT03460743 Comparator	Mar 2018 → Oct 2019	influenza	Laboratorios Liomont	Completed	No outcome recorded
Phase 3	NCT03285997 Comparator	Sep 2017 → May 2018	—	Green Cross Corporation	Unknown	No outcome recorded
Phase 3	NCT02914275 Comparator	Sep 2016 → Mar 2017	influenza	Seqirus	Completed	No outcome recorded
Phase 3	NCT02541253 Comparator	Sep 2015 → Jun 2016	influenza	Green Cross Corporation	Completed	No outcome recorded
Phase 3	NCT02550197 Comparator	Sep 2015 → Apr 2016	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT02242643 Comparator	Oct 2014 → Mar 2015	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02285998 Comparator	Oct 2014 → May 2015	influenza	Protein Sciences Corporation	Completed	No outcome recorded
Phase 3	NCT02255279 Comparator	Oct 2014 → May 2015	influenza	Novartis Vaccines	Completed	No outcome recorded
Phase 3	NCT01959945 Comparator	Nov 2013 → Jun 2014	influenza	Protein Sciences Corporation	Completed	No outcome recorded
Phase 3	NCT02263131 Comparator	Oct 2013 → Jan 2014	—	Il-Yang Pharm. Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT01773928 Comparator	Jan → Apr 2013	influenza	Alachua Government Services, Inc.	Completed	No outcome recorded
Phase 3	NCT01711736 Comparator	Nov 2012 → Feb 2013	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01481454 Comparator	Mar → Oct 2012	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT01306669 Comparator	Mar 2011 → May 2013	influenza	University of Witwatersrand, South Africa	Completed	No outcome recorded
Phase 3	NCT01218646 Comparator	Oct 2010 → Mar 2011	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT00980005 Comparator	Oct 2009 → Mar 2010	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00976027 Comparator	Sep 2009 → May 2011	influenza	Sanofi	Terminated	No outcome recorded
Phase 3	NCT00959049 Comparator	Sep → Dec 2009	influenza	Seqirus	Completed	No outcome recorded
Phase 3	NCT01554826 Comparator	Mar → May 2009	influenza	Hualan Biological Engineering, Inc.	Completed	No outcome recorded
Phase 3	NCT00765076 Comparator	Oct 2008 → Dec 2009	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00772889 Comparator	Oct 2008 → Dec 2009	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00760617 Comparator	Oct 2008 → May 2009	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00764790 Comparator	Oct 2008 → Mar 2009	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00753272 Comparator	Sep 2008 → Jun 2010	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00529516 Comparator	Oct → Dec 2007	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00492557 Background	Sep 2007 → Feb 2008	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT00539864 Comparator	Sep 2007 → Apr 2008	influenza	Protein Sciences Corporation	Completed	No outcome recorded
Phase 3	NCT00383123 Comparator	Nov 2006 → Oct 2007	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00385255 Background	Oct 2006 → Feb 2007	diphtheria, tetanus	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00383526 Comparator	Sep 2006 → Jun 2009	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT00383539 Comparator	Sep 2006 → Jul 2007	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT00319098 Comparator	May 2006 → Jan 2007	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00885105 Comparator	Oct 2005 → Jan 2006	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT00231816 Background	Sep 2005 → Mar 2006	herpes zoster	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT01389479 Comparator	Jan → May 2005	influenza	GlaxoSmithKline	Completed	No outcome recorded

Phase 441 trials
Phase 4	NCT07177417 Comparator	Sep 2025 → Sep 2026 expected	—	Washington University School of Medicine	Recruiting	No outcome recorded
Phase 4	NCT06336317 Comparator	Apr 2024 → Dec 2027 expected	acute myocardial infarction, inflammatory disease	Region Örebro County	Recruiting	No outcome recorded
Phase 4	NCT06024096 Comparator	Sep 2023 → Dec 2024	—	Emory University	Completed	No outcome recorded
Phase 4	NCT05514002 Comparator	Sep 2022 → Dec 2023	influenza	Fatimah Dawood	Terminated	No outcome recorded
Phase 4	NCT04101838 Comparator	Apr 2021 → May 2026 overdue	influenza	University of Alabama at Birmingham	Active not recruiting	No outcome recorded
Phase 4	NCT03969641 Comparator	Sep 2019 → Sep 2021	—	Duke University	Completed	No outcome recorded
Phase 4	NCT03600428 Comparator	Oct 2018 → Mar 2020	childhood onset asthma, influenza, vaccinia	Vanderbilt University Medical Center	Completed	No outcome recorded
Phase 4	NCT03694808 Comparator	Sep 2018 → Jan 2023	influenza	David H. Canaday	Completed	No outcome recorded
Phase 4	NCT03614975 Comparator	Sep → Dec 2018	influenza	Richard Zimmerman MD	Completed	No outcome recorded
Phase 4	NCT03722589 Comparator	Sep 2018 → Jul 2020	influenza	Centers for Disease Control and Prevention	Completed	No outcome recorded
Phase 4	NCT03603509 Comparator	Aug 2018 → Jan 2019	influenza	Mayo Clinic	Completed	No outcome recorded
Phase 4	NCT03183908 Comparator	Aug 2017 → Feb 2019	—	Duke University	Completed	No outcome recorded
Phase 4	NCT02871206 Comparator	Nov 2016 → Jun 2019	influenza	McMaster University	Completed	No outcome recorded
Phase 4	NCT02967393 Comparator	Oct 2016 → Feb 2017	asthma	Vanderbilt University Medical Center	Completed	No outcome recorded
Phase 4	NCT03955991 Background	Jul 2016 → Jun 2024	—	University of Miami	Completed	No outcome recorded
Phase 4	NCT03068949 Comparator	Oct 2015 → Jun 2020	influenza	University of Rochester	Completed	No outcome recorded
Phase 4	NCT02563184 Comparator	Sep → Dec 2015	chronic obstructive pulmonary disease	Banner Health	Unknown	No outcome recorded
Phase 4	NCT02565277 Comparator	Sep 2015 → Dec 2018	autoinflammatory syndrome	Health Sciences North Research Institute	Completed	No outcome recorded
Phase 4	NCT03502291 Comparator	Aug 2015 → May 2017	influenza, pneumonia	Liverpool University Hospitals NHS Foundation Trust	Completed	No outcome recorded
Phase 4	NCT02297542 Comparator	Oct 2014 → Dec 2019	—	Health Sciences North Research Institute	Unknown	No outcome recorded
Phase 4	NCT02640989 Comparator	Oct 2014	influenza	Center for Disease Prevention and Control of Beijing Military Region	Completed	No outcome recorded
Phase 4	NCT02212106 Comparator	Sep → Dec 2014	influenza	Seqirus	Completed	No outcome recorded
Phase 4	NCT02268500 Comparator	Sep 2014 → Jan 2016	heart failure	University of Wisconsin, Madison	Completed	No outcome recorded
Phase 4	NCT02062281 Comparator	Nov → Dec 2013	influenza, pneumococcal infection	Jiangsu Province Centers for Disease Control and Prevention	Completed	No outcome recorded
Phase 4	NCT01967368 Comparator	Oct 2013 → May 2014	influenza	The University of Hong Kong	Unknown	No outcome recorded
Phase 4	NCT01808456 Comparator	Oct 2013 → Dec 2016	disease related to transplantation, influenza	Inova Health Care Services	Completed	No outcome recorded
Phase 4	NCT01815268 Comparator	Feb 2013 → May 2017	influenza	Insight Therapeutics, LLC	Unknown	No outcome recorded
Phase 4	NCT01730378 Comparator	Dec 2012 → Dec 2013	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01691339 Comparator	Sep → Nov 2012	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT01698177 Comparator	Oct 2011 → Jun 2013	influenza	Stony Brook University	Unknown	No outcome recorded
Phase 4	NCT01427309 Comparator	Sep 2011 → May 2013	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT01430819 Comparator	Sep 2011 → Feb 2012	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT01368796 Comparator	Jul → Dec 2011	—	University of British Columbia	Completed	No outcome recorded
Phase 4	NCT03101462 Comparator	Feb → May 2011	influenza	St. Louis University	Completed	No outcome recorded
Phase 4	NCT02440243 Comparator	Jan 2011 → Sep 2014	allergic disease	Medical University of Silesia	Completed	No outcome recorded
Phase 4	NCT01215669 Comparator	Oct 2010 → Feb 2011	influenza	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 4	NCT01246999 Comparator	Oct 2010 → Jan 2013	influenza	University of Rochester	Completed	No outcome recorded
Phase 4	NCT01194297 Comparator	Aug 2010 → May 2012	influenza	University of Rochester	Terminated	No outcome recorded
Phase 4	NCT00735475 Comparator	Oct 2008 → Jan 2009	influenza	Seqirus	Completed	No outcome recorded
Phase 4	NCT00538512 Comparator	Sep 2007 → May 2008	influenza	University of Michigan	Completed	No outcome recorded
Phase 4	NCT00664339 Comparator	May 2007 → Mar 2008	heart failure	La Fundacion Favaloro para la Investigacion y la Docencia Medica	Completed	No outcome recorded

Phase not applicable21 trials
—	NCT06041867 Background	Sep → Dec 2023	—	Maastricht University Medical Center	Completed	No outcome recorded
—	NCT05706350 Background	Oct → Dec 2022	—	Maastricht University Medical Center	Completed	No outcome recorded
—	NCT04188483 Background	Oct → Dec 2019	—	Huazhong University of Science and Technology	Completed	No outcome recorded
—	NCT01962636 Background	Dec 2016 → May 2026	Burkitt lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia +11	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
—	NCT02872311 Comparator	Sep 2016 → Apr 2018	—	Marshfield Clinic Research Foundation	Completed	No outcome recorded
—	NCT04122222 Comparator	Aug 2016 → Jul 2018	—	Mahidol University	Completed	No outcome recorded
—	NCT02262091 Background	Aug → Dec 2014	—	Nestlé	Completed	No outcome recorded
—	NCT01302821 Background	Jan 2013 → Dec 2014	breast cancer	H. Lee Moffitt Cancer Center and Research Institute	Withdrawn	No outcome recorded
—	NCT01707628 Comparator	Oct 2012 → Jun 2013	non-Hodgkin lymphoma	St. Antonius Hospital	Completed	No outcome recorded
—	NCT01737710 Comparator	Oct 2012 → May 2013	atopic eczema	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT01522248 Comparator	Jan → Feb 2012	—	Johns Hopkins Bloomberg School of Public Health	Completed	No outcome recorded
—	NCT01508884 Comparator	Jan → Dec 2012	—	The University of Hong Kong	Completed	No outcome recorded
—	NCT01215981 Comparator	Sep 2010 → Jun 2011	disease related to hematopoietic stem cell transplant, hematopoietic and lymphoid cell neoplasm	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
—	NCT01189123 Comparator	Aug 2010 → Aug 2011	—	Vanderbilt University	Completed	No outcome recorded
—	NCT01568788 Comparator	Dec 2008 → Jan 2009	influenza	Hualan Biological Engineering, Inc.	Completed	No outcome recorded
—	NCT00760175 Comparator	Oct 2008 → Dec 2009	influenza	University of Alberta	Completed	No outcome recorded
—	NCT00902278 Comparator	Oct 2008 → Apr 2016	—	University of Massachusetts, Worcester	Completed	No outcome recorded
—	NCT00769002 Comparator	Sep 2008 → Aug 2011	influenza	Hackensack Meridian Health	Terminated	No outcome recorded
—	NCT00792051 Comparator	Sep 2008 → Dec 2010	influenza	The University of Hong Kong	Completed	No outcome recorded
—	NCT00570037 Comparator	Oct 2007 → Apr 2008	influenza	Duke University	Completed	No outcome recorded
—	NCT00679237 Comparator	Sep 2007 → Dec 2019	coronary artery disorder	Sorlandet Hospital HF	Completed	No outcome recorded

Press releases naming this drug 266 releases

Date	Issuer	Release
2026-07-29	Pfizer	European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union pfizer.com ↗
2026-05-20	Pfizer	Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results pfizer.com ↗
2026-04-18	Sanofi	Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study sanofi.com ↗
2026-03-23	Pfizer	Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial pfizer.com ↗
2025-12-24	Sanofi	Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline sanofi.com ↗
2025-10-20	Sanofi	Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose sanofi.com ↗
2025-10-17	CSL Behring	CSL Seqirus Presents Latest Research Across Leading Seasonal Influenza Vaccine Portfolio at ESWI 2025 csl.com ↗
2025-09-08	Pfizer	Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula pfizer.com ↗
2025-07-25	Pfizer	Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union pfizer.com ↗
2025-04-16	Pfizer	ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease pfizer.com ↗
2025-04-01	Pfizer	European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease pfizer.com ↗
2025-03-26	Sanofi	Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA sanofi.com ↗
Show all 266 releases opens the full record — a long page

Evidence & citations 131 cited values

Every value below carries the sentence it was read from. 505 sources stand behind the page.

Field	Value	Cited text
Known as	Influenza Virus Vaccine	“Fluzone (Influenza Virus Vaccine) Suspension for Intramuscular Injection 2013-2014 Formula.” NCT03020537 ↗ 11 NCT00700193 ↗ NCT00835926 ↗ NCT01000246 ↗ NCT02649192 ↗ NCT00006146 ↗ NCT00885105 ↗ NCT00001080 ↗ NCT00617851 ↗ NCT00389532 ↗ NCT01551810 ↗ NCT06382311 ↗
Known as	2006-2007 Fluzone vaccine	“2006-2007 Fluzone® vaccine” NCT00389532 ↗
Known as	2007-2008 Influenza Virus Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00561002 ↗
Known as	2008-2009 Trivalent Influenza Virus Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00988143 ↗
Known as	2009-2010 Trivalent Influenza Virus Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00988143 ↗
Known as	2016-2017 Flu vaccine	“2016-2017 Flu vaccine” NCT02783170 ↗
Known as	2016-2017 Quadrivalent Inactivated Influenza Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02783170 ↗
Known as	2017-2018 Flu vaccine	“2017-2018 Flu vaccine” NCT02783170 ↗
Known as	2017-2018 Quadrivalent Inactivated Influenza Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02783170 ↗
Known as	Adenovirus-p53 transduced dendritic cell vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01302821 ↗
Known as	Adjuvanted Fluarix	“influenza vaccine Fluarix, Adjuvanted Fluarix” NCT00318058 ↗
Known as	AlloCB	“AIM: To evaluate safety and motor function after treatment with allogeneic umbilical cord blood (AlloCB) or umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in...” PMID 35811372 ↗ Jul 2022
Known as	allogeneic umbilical cord blood	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02397018 ↗ 2 NCT01451528 ↗ NCT03473301 ↗
Known as	Alpha-Rix	“Fluarix™ (Known as Alpha-Rix™ in Belgium)” NCT00318149 ↗
Known as	bioCSL Split Virion, Inactivated Influenza Vaccine	“A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2013/2014 Formulation of a bioCSL Split Virion, Inactivated Influenza Vaccine in...” NCT01863433 ↗
Known as	Brand Name: VAXIGRIP	“Brand Name: VAXIGRIP” NCT00961337 ↗
Known as	C-IIV4	“a United States (US)-licensed comparator IIV4 (C-IIV4; Fluzone® Quadrivalent; n=563) during the Northern Hemisphere 2016-2017 influenza season” PMID 30057283 ↗ Jul 2018
Known as	Comparator Quadrivalent Influenza Virus Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02212106 ↗
Known as	Cord Blood	“Cord Blood infusion will occur on day 0” NCT01328496 ↗ 7 NCT02847182 ↗ NCT02838992 ↗ NCT01408563 ↗ NCT02668315 ↗ NCT01763099 ↗ NCT00305344 ↗ NCT02434965 ↗
Known as	Dendritic Cell (DC1) vaccine	“The purpose of the study is to find out if an investigational drug called Dendritic Cell (DC1) vaccine added to standard neoadjuvant (given before main treatment) therapy can...” NCT05325632 ↗
Known as	Egg-based Quadrivalent Influenza Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05606965 ↗
Known as	Enzira Vaccine	“A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers” NCT01863433 ↗
Known as	FLU vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05568797 ↗ 3 NCT00558649 ↗ NCT00664339 ↗ NCT01967238 ↗
Known as	Fluad H5N1 Pandemic Influenza Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00478816 ↗
Known as	Fluarix	“Study subjects will be randomized 1:1:1 to receive one of the following three 2010-2011 seasonal inactivated trivalent influenza vaccines: Fluarix®, Agriflu®, or Fluzone® (60...” NCT01173211 ↗ 66 “A trivalent inactivated influenza vaccine (Fluarix (™) , GlaxoSmithKline Biologicals) was licensed under US accelerated approval regulations.” PMID 21285532 ↗ Jan 2011 “Study Regimen/Intervention: This is a double blind RCT of two vaccines (Pneumovax®23 and Fluarix®) plus placebo (sterile saline injection).” NCT02707692 ↗ “Compared With Fluarix™ Administered Intramuscularly in Elderly Aged 60 Years Old and Above” NCT00321373 ↗ “GSK Biologicals' Influenza Vaccine (Fluarix™) Administered Intramuscularly in Adults.” NCT00197223 ↗ “received 1 dose of Fluarix® vaccine at Day 0” NCT00693706 ↗ “vaccine (FLuarix, Influvac etc)” NCT00679237 ↗ “Fluarix (age 3y and older)” NCT01248208 ↗ “Flu Vaccine (FLUARIX®)” NCT00558649 ↗ “Fluarix” NCT04484532 ↗ NCT00538473 ↗ NCT01144299 ↗ NCT00765076 ↗ NCT00476307 ↗ NCT00545025 ↗ NCT00321373 ↗ NCT00764790 ↗ NCT00321763 ↗ NCT05479370 ↗ NCT00540228 ↗ NCT00540592 ↗ NCT00319098 ↗ NCT00968890 ↗ NCT00971425 ↗ NCT00318149 ↗ NCT00345904 ↗ NCT00318058 ↗ NCT03339713 ↗ NCT00985790 ↗ NCT05170399 ↗ NCT00760617 ↗ NCT00100399 ↗ NCT00538213 ↗ NCT01196026 ↗ NCT01195779 ↗ NCT01096056 ↗ NCT00397215 ↗ NCT02640989 ↗ NCT00532298 ↗ NCT02707692 ↗ NCT01730378 ↗ NCT00693706 ↗ NCT01959945 ↗ NCT00453986 ↗ NCT00363077 ↗ NCT00386698 ↗ NCT00386113 ↗ NCT06602024 ↗ NCT00363870 ↗ NCT00902278 ↗ NCT00385255 ↗ NCT00772889 ↗ NCT00442975 ↗ NCT01711736 ↗ NCT02330003 ↗ NCT00383123 ↗ NCT00753272 ↗ NCT03722589 ↗ NCT00529516 ↗ NCT00380211 ↗ NCT00502593 ↗ NCT00706563 ↗ NCT00905125 ↗ NCT00374842 ↗ NCT00920374 ↗ NCT00377585 ↗ NCT00377611 ↗
Known as	Fluarix Quadrivalent	“one of two standard dose egg-based vaccines (Fluzone® Quadrivalent by Sanofi Pasteur, 15µg of HA per strain and Fluarix® Quadrivalent by GlaxoSmithKlein, 15µg of HA per strain)” NCT03722589 ↗
Known as	Flubio	“Flubio (Influenza HA) Vaccine” NCT02093260 ↗ 1 NCT03695432 ↗
Known as	Flulaval	“Experimental group given influenza vaccine (Flulaval)” NCT05654441 ↗ 7 “licensed 2008/2009 FluLaval(Registered Trademark)” NCT00858611 ↗ “FluLaval (age 18y and older)” NCT01248208 ↗ “FluLaval” NCT04484532 ↗ NCT05170399 ↗ NCT00858611 ↗ NCT01059617 ↗ NCT00902278 ↗
Known as	FluShield	“Flushield” NCT04484532 ↗ 1 NCT00769002 ↗
Known as	FluVac	“influenza vaccine (FluVac)” PMID 40432084 ↗ Apr 2025
Known as	FluvalAB adjuvanted trivalent seasonal influenza vaccine	“FluvalAB adjuvanted trivalent seasonal influenza vaccine” NCT01119157 ↗
Known as	Fluzone	“Study subjects will be randomized 1:1:1 to receive one of the following three 2010-2011 seasonal inactivated trivalent influenza vaccines: Fluarix®, Agriflu®, or Fluzone® (60...” NCT01173211 ↗ 93 “The purpose of this study is to compare two licensed influenza vaccines (Fluzone and Fluarix) in terms of the immune response elicited and the safety/ any symptoms that may...” NCT00197288 ↗ “Licensed trivalent influenza vaccine (TIV): 2005-2006 formulation containing 15μg of each hemagglutinin derived from A/Wisconsin (H3N2), A/New Caledonia (H1N1) and...” NCT00395174 ↗ “Either a standard pediatric dose (0.25 ml) or a larger dose (0.5 ml) of Trivalent Inactivated Influenza Vaccine (TIV) (Fluzone®) administered intramuscularly (IM) in the thigh...” NCT01164553 ↗ “2006-2007 formulation of Fluzone, (sanofi-pasteur, Swiftwater, PA)-7.5 μg of each hemagglutinin antigen: A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and...” NCT00336453 ↗ “MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric...” PMID 28925801 ↗ Jan 2018 “The purpose of this study is to generate additional data on the immunogenicity and safety of revaccination with Fluzone Intradermal (ID) or Fluzone Intramuscular (IM) vaccine.” NCT01011049 ↗ “A Non-Inferiority Comparison of Fluviral™ Influenza Vaccine to a U.S. Licensed Inactivated Split-Virion Vaccine (Fluzone®) in Adults ≥ 50 Years Old Living in the Community” NCT00232947 ↗ “Standard Dose Influenza Vaccine Fluzone® (15 µg HA / viral strain; 45 µg/0.5 mL dose) will be administered to Arm 1: 200 subjects intramuscularly on day 0.” NCT00115531 ↗ “2005-6 Fluzone, pediatric formulation of trivalent inactivated influenza vaccine (sanofi pasteur) administered to infants at 2 and 3 months of age” NCT00242424 ↗ “Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® [15 mcg x 3 strains]), as a single intramuscular dose.” NCT01436370 ↗ “The aim of this study is to determine the efficacy of Fluzone High Dose vaccine and that of Fluzone® vaccine in the elderly.” NCT00976027 ↗ “0.5 mL of Fluzone (2011-2012 Northern Hemisphere formulation) influenza vaccine administered via subcutaneous route once” NCT01422200 ↗ “older adults (≥65 years, n=582) were randomized to receive SD-SVV or HD-SVV (Fluzone®) from 2014/15 to 2017/18” PMID 35128529 ↗ May 2021 “Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age” NCT02559505 ↗ “trivalent inactivated influenza vaccine (TIV, Fluzone®, sanofi pasteur 2005-6 pediatric formulation)” NCT00242424 ↗ “the 2003-2004 pediatric formulation of the inactivated, split-virion influenza vaccine Fluzone®” NCT00836953 ↗ “0.5 ml of Inactivated Trivalent Influenza Vaccine (TIV), Fluzone® given intramuscularly (IM)” NCT01181323 ↗ “the 2008-2009 formulation of the inactivated, split-virion influenza vaccine Fluzone®” NCT00755274 ↗ “2018/2019 seasonal Fluzone or Flublok Quadrivalent Influenza Vaccine (QIV)” NCT03945825 ↗ “Fluzone® (QuadriFlu - TIV), inactivated, quadrivalent influenza vaccine” NCT03926416 ↗ “Fluzone, high-dose split virion influenza virus vaccine, Sanofi Pasteur” NCT04176133 ↗ “standard-dose (SD) IM vaccine (Fluzone(®); 15μg HA/strain; n=319)” PMID 24120672 ↗ Oct 2013 “Fluzone (approved for children down to 6 months)” NCT01248208 ↗ “Administration of Fluzone (Influenza Vaccine)” NCT01733056 ↗ “High Dose Fluzone by sanofi pasteur” NCT01189123 ↗ “45 micrograms Fluzone” NCT01302990 ↗ “Fluzone®” NCT00976027 ↗ NCT02141581 ↗ NCT03028974 ↗ NCT03028987 ↗ NCT01354379 ↗ NCT03023553 ↗ NCT00538512 ↗ NCT03023709 ↗ NCT00735475 ↗ NCT01987349 ↗ NCT00764790 ↗ NCT01974895 ↗ NCT00539864 ↗ NCT03022396 ↗ NCT05291676 ↗ NCT02563184 ↗ NCT03020537 ↗ NCT06567860 ↗ NCT00623181 ↗ NCT03020498 ↗ NCT01691326 ↗ NCT01737710 ↗ NCT01691339 ↗ NCT01773928 ↗ NCT00283283 ↗ NCT02134184 ↗ NCT02133781 ↗ NCT00936468 ↗ NCT02263040 ↗ NCT00831987 ↗ NCT02267733 ↗ NCT04101838 ↗ NCT05170399 ↗ NCT01218646 ↗ NCT06518577 ↗ NCT03068949 ↗ NCT00253734 ↗ NCT02871206 ↗ NCT01430819 ↗ NCT00133510 ↗ NCT03614975 ↗ NCT00389857 ↗ NCT00232947 ↗ NCT03453801 ↗ NCT00743275 ↗ NCT00231920 ↗ NCT00231907 ↗ NCT01262846 ↗ NCT01044095 ↗ NCT00959049 ↗ NCT00902278 ↗ NCT01685372 ↗ NCT00383123 ↗ NCT01224262 ↗ NCT00258817 ↗ NCT01644149 ↗ NCT00258830 ↗ NCT03722589 ↗ NCT01385215 ↗ NCT02918006 ↗ NCT00905125 ↗ NCT01831934 ↗ NCT00170508 ↗ NCT01389479 ↗ NCT00138281 ↗ NCT00138385 ↗ NCT00980005 ↗
Known as	Fluzone (2012-2013 Formulation)	“Fluzone® (2012-2013 Formulation)” NCT01691339 ↗
Known as	Fluzone (Influenza Virus Vaccine) 2012-2013 Formulation	“Fluzone® (Influenza Virus Vaccine) 2012-2013 Formulation” NCT01691326 ↗
Known as	fluzone by sanofi pasteur	“Biological: fluzone by sanofi pasteur” NCT01189123 ↗
Known as	Fluzone HD	“The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain...” NCT03699839 ↗ 11 “Licensed and FDA approved Fluzone HD vaccine to be administered to study participants” NCT02872311 ↗ “High-dose influenza vaccine (Fluzone® HD)” NCT03183908 ↗ “IIV, Fluzone HD 60 µg per HA” PMID 35125224 ↗ Feb 2022 “Fluzone HD” NCT05827978 ↗ NCT06060457 ↗ NCT03658629 ↗ NCT03068949 ↗ NCT05163847 ↗ NCT03694808 ↗ NCT03293498 ↗ NCT06431607 ↗
Known as	Fluzone High Dose	“0.5mL Fluzone® High-Dose, Sanofi Pasteur containing 180μg antigen; 60μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.” NCT03330132 ↗ 19 “Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs.” NCT05947071 ↗ “Fluzone High-Dose is an injectable influenza vaccine made to protect against the flu strains most likely to cause illness for that particular flu season.” NCT02868970 ↗ “Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® High Dose [60 mcg x 3 strains]), as a single intramuscular dose.” NCT01436370 ↗ “Fluzone High-Dose (Influenza Vaccine) for intramuscular use is an inactivated influenza vaccine” NCT07192458 ↗ “Fluzone High-Dose is supplied as a suspension for IM injection 0.5 mL with 60 µg per strain” NCT06291857 ↗ “Fluzone High-Dose 0.7 ml intramuscular injection, standard as recommended by manufacturer” NCT05291676 ↗ “Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation” NCT01691339 ↗ “Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation” NCT01430819 ↗ “Fluzone® High-dose Group” NCT00551031 ↗ NCT02563093 ↗ NCT02831751 ↗ NCT03183908 ↗ NCT04101838 ↗ NCT03603509 ↗ NCT04143451 ↗ NCT05663463 ↗ NCT03722589 ↗ NCT02908269 ↗ NCT01946438 ↗
Known as	Fluzone High-Dose (2012-2013 Formulation)	“Fluzone® High-Dose (2012-2013 Formulation)” NCT01691339 ↗
Known as	Fluzone High-dose (HD)	“Fluzone High-dose (HD)” NCT04484532 ↗
Known as	Fluzone High-Dose Quadrivalent	“licensed inactivated influenza vaccine (Fluzone High-Dose Quadrivalent; hereafter referred to as Fluzone HD)” PMID 39004096 ↗ Jul 2024
Known as	Fluzone High-Dose, Influenza Vaccine	“Fluzone® High-Dose, Influenza Vaccine” NCT02563093 ↗ 1 “Fluzone® High-Dose Influenza Vaccine” NCT02908269 ↗
Known as	Fluzone High-Dose, Influenza Virus Vaccine	“Fluzone® High-Dose, Influenza Virus Vaccine” NCT01946438 ↗
Known as	Fluzone Influenza Vaccine (2007-2008)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00504231 ↗
Known as	Fluzone Quadrivalent	“Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses...” NCT04613206 ↗ 20 “Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses...” NCT05947071 ↗ “one of two standard dose egg-based vaccines (Fluzone® Quadrivalent by Sanofi Pasteur, 15µg of HA per strain and Fluarix® Quadrivalent by GlaxoSmithKlein, 15µg of HA per strain)” NCT03722589 ↗ “a United States (US)-licensed comparator IIV4 (C-IIV4; Fluzone® Quadrivalent; n=563) during the Northern Hemisphere 2016-2017 influenza season” PMID 30057283 ↗ Jul 2018 “Treatment Groups Flublok® Quadrivalent (research product) Fluzone® Quadrivalent (active comparator)” NCT03460743 ↗ “a single dose of SD IIV (Fluzone® Quadrivalent by Sanofi Pasteur, 15 µg of HA per strain)” NCT05514002 ↗ “Fluzone® Quadrivalent: Quadrivalent influenza virus vaccine” NCT03028974 ↗ “Fluzone® Quadrivalent” NCT05050318 ↗ NCT02242643 ↗ NCT05050318 ↗ NCT02563093 ↗ NCT04304768 ↗ NCT06067555 ↗ NCT04120194 ↗ NCT03312699 ↗ NCT03926416 ↗ NCT05514002 ↗ NCT06229392 ↗ NCT02908269 ↗ NCT01946438 ↗ NCT02434276 ↗
Known as	Fluzone Quadrivalent, Influenza Vaccine	“Fluzone® Quadrivalent, Influenza Vaccine” NCT02563093 ↗ 1 “Fluzone® Quadrivalent, Influenza Vaccine” NCT02908269 ↗
Known as	Fluzone Quadrivalent, Influenza Virus Vaccine	“Fluzone® Quadrivalent, Influenza Virus Vaccine” NCT01946438 ↗
Known as	Fluzone SD	“standard dose IIV (Fluzone SD, 15 µg per HA)” PMID 35125219 ↗ Feb 2022
Known as	Fluzone Trivalent	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06664151 ↗
Known as	Fluzone Trivalent High-Dose	“Fluzone® Trivalent High-Dose by Sanofi Pasteur, 60µg of HA per strain” NCT03722589 ↗
Known as	Fluzone vaccine	“Fluzone vaccine administered in both May-June and in September-October for each participant.” NCT06567860 ↗ 1 NCT00662272 ↗
Known as	GCFLU Pre-filled Syringe inj.	“GC Flu Pre-filled Syringe Inj. (a marketed TIV)” NCT02121782 ↗ 2 NCT02541253 ↗ NCT03285997 ↗
Known as	GlaxoSmithKline Biologicals' licensed influenza vaccine	“GlaxoSmithKline Biologicals' licensed influenza vaccine” NCT00318149 ↗
Known as	GSK Biologicals' FluLaval	“GSK Biologicals' FluLaval®” NCT01059617 ↗
Known as	HD Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01815268 ↗
Known as	HD-IIV3	“adjuvanted flu vaccine (aTIV, FLUAD) vs high-dose flu vaccine (HD-IIV3, FLUZONE HD)” PMID 40373825 ↗ May 2025
Known as	HD-TIV	“We demonstrated in a primary phase 2 randomized controlled trial that 2 post-HCT doses of high-dose trivalent influenza vaccine (HD-TIV) given 4 weeks apart were more...” PMID 39279435 ↗ Feb 2025 1 “High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)” NCT01215734 ↗
Known as	Hematopoietic stem cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07524530 ↗
Known as	HER-2 pulsed DC1	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05325632 ↗ 1 NCT02336984 ↗
Known as	HER2 DC1 Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03630809 ↗
Known as	High dose fluzone (Sanofi-Pasteur)	“High dose fluzone (Sanofi-Pasteur)” NCT01189123 ↗
Known as	High-Dose Inactivated, Split-Virion Influenza Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00391053 ↗
Known as	High-Dose Influenza Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04024228 ↗ 1 NCT01666782 ↗
Known as	High-Dose Influenza Virus Vaccine	“High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe” NCT03022435 ↗
Known as	High-Dose TIV	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03022435 ↗ 1 NCT03022422 ↗
Known as	High-dose trivalent inactivated influenza vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02553343 ↗ 3 NCT01215734 ↗ NCT01258595 ↗ NCT01525004 ↗
Known as	high-dose trivalent influenza vaccine	“We demonstrated in a primary phase 2 randomized controlled trial that 2 post-HCT doses of high-dose trivalent influenza vaccine (HD-TIV) given 4 weeks apart were more...” PMID 39279435 ↗ Feb 2025
Known as	HPC, Cord Blood	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03735277 ↗
Known as	hUCB	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06040476 ↗
Known as	IAIV	“The current standard of care for HIV infected children is vaccination with an inactivated influenza vaccine (IAIV).” NCT00091702 ↗
Known as	IIV	“Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) were administered to eligible children through a research program to improve vaccination...” NCT00138294 ↗ 1 “Quadrivalent inactivated influenza vaccine (IIV), Intramuscular Injection” NCT03888989 ↗
Known as	IIV Flu Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02154061 ↗
Known as	IIV3	“METHODS: We conducted two double-blind, randomized, placebo-controlled trials of trivalent inactivated influenza vaccine (IIV3) in South Africa during 2011 in pregnant women...” PMID 25184864 ↗ Sep 2014 4 “BACKGROUND: Few data exist on the immunogenicity and safety of an inactivated enterovirus 71 vaccine (EV71 vaccine) coadministered with trivalent split-virion inactivated...” PMID 36569946 ↗ Dec 2022 “BACKGROUND: We report results of years 2 and 3 of consecutive cluster-randomized controlled trials of trivalent inactivated influenza vaccine (IIV3) in Senegal.” PMID 33165566 ↗ Jun 2021 “the licensed split-virion trivalent inactivated influenza vaccine (IIV3) in the Republic of Korea” PMID 28933625 ↗ Nov 2017 “standard-dose trivalent inactivated influenza vaccination (IIV3)” PMID 30277500 ↗ Jun 2019
Known as	IIV4	“This trial compared the protective efficacy in older adults of a quadrivalent, recombinant influenza vaccine (RIV4) with a standard-dose, egg-grown, quadrivalent, inactivated...” PMID 28636855 ↗ Jun 2017 12 “Participants will receive the current seasonal quadrivalent, inactivated influenza vaccine (IIV4)/Fluzone® given intramuscularly to confirm the safety of administering the...” NCT03023709 ↗ “a third booster dose of SARS-CoV-2 inactivated vaccine (CoronaVac), inactivated quadrivalent influenza vaccine (IIV4), and 23-valent pneumococcal polysaccharide vaccine (PPV23)” PMID 39229259 ↗ Aug 2024 “This study assessed the immunogenicity and safety of a quadrivalent influenza split-virion vaccine (IIV4) in children with and without prior influenza vaccination.” PMID 39993940 ↗ Feb 2025 “Quadrivalent inactivated influenza vaccine (IIV4)” NCT05144945 ↗ “quadrivalent inactivated influenza vaccine (IIV4)” PMID 35342923 ↗ Apr 2022 NCT05028361 ↗ NCT02967393 ↗ NCT04790851 ↗ NCT05480436 ↗ NCT06503900 ↗ NCT05079152 ↗ NCT04559204 ↗
Known as	Inactivated Influenza Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03101462 ↗ 15 NCT02500680 ↗ NCT01194297 ↗ NCT07177417 ↗ NCT03315975 ↗ NCT05606965 ↗ NCT00741039 ↗ NCT00792051 ↗ NCT02285998 ↗ NCT00091702 ↗ NCT01568788 ↗ NCT00888381 ↗ NCT04998344 ↗ NCT00906750 ↗ NCT01554826 ↗ NCT00138294 ↗
Known as	Inactivated influenza vaccine (split virion) NH 2007-2008 formulation	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00491257 ↗
Known as	Inactivated Influenza Vaccine of GSK	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01568788 ↗
Known as	Inactivated Influenza Vaccine of Pasteur	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01568788 ↗
Known as	Inactivated split virion Influenza vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01465477 ↗ 6 NCT00391053 ↗ NCT00383526 ↗ NCT00383539 ↗ NCT00296829 ↗ NCT00258934 ↗ NCT00703651 ↗
Known as	influenza trivalent inactive vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01808456 ↗
Known as	Influenza Vaccination	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00822627 ↗ 5 NCT01666535 ↗ NCT00877396 ↗ NCT07617376 ↗ NCT00222638 ↗ NCT04188483 ↗
Known as	Influenza vaccine	“Participants received any control (placebo, Tdap or influenza vaccine) during the prior RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV...” NCT05705440 ↗ 74 “Influenza Vaccine recommended by World Health Organization(WHO) in that year and imported 23-Valent Pneumococcal Polysaccharide Vaccine approved by China Food and Drug...” NCT03449459 ↗ “Participants >= 12 years received influenza vaccine of Northern and Southern hemisphere formulations at second (Month 6) and third (Month 12) vaccinations.” NCT00880893 ↗ “Influenza vaccine” NCT01072734 ↗ NCT00466037 ↗ NCT01488188 ↗ NCT03028116 ↗ NCT01508884 ↗ NCT00735020 ↗ NCT02545868 ↗ NCT00868218 ↗ NCT01013675 ↗ NCT06336317 ↗ NCT07587801 ↗ NCT06097273 ↗ NCT00915187 ↗ NCT02831608 ↗ NCT00607217 ↗ NCT03666806 ↗ NCT01215981 ↗ NCT00607178 ↗ NCT02565277 ↗ NCT01034254 ↗ NCT01273974 ↗ NCT05294588 ↗ NCT03996538 ↗ NCT01707628 ↗ NCT05074303 ↗ NCT02262091 ↗ NCT04091880 ↗ NCT06355232 ↗ NCT00408395 ↗ NCT06091410 ↗ NCT02655874 ↗ NCT04526574 ↗ NCT02653495 ↗ NCT02268500 ↗ NCT02947217 ↗ NCT01924169 ↗ NCT03572491 ↗ NCT02946177 ↗ NCT00214071 ↗ NCT02415166 ↗ NCT00596336 ↗ NCT00316628 ↗ NCT00316615 ↗ NCT05091307 ↗ NCT03658629 ↗ NCT06041867 ↗ NCT05909423 ↗ NCT03756246 ↗ NCT07259252 ↗ NCT01403376 ↗ NCT00918268 ↗ NCT03748524 ↗ NCT06279871 ↗ NCT00999206 ↗ NCT02665871 ↗ NCT02290691 ↗ NCT05616546 ↗ NCT05706350 ↗ NCT00231816 ↗ NCT01761435 ↗ NCT01698177 ↗ NCT06602531 ↗ NCT02998736 ↗ NCT01693380 ↗ NCT05116917 ↗ NCT03277703 ↗ NCT05654441 ↗ NCT01002508 ↗ NCT02311855 ↗ NCT03955991 ↗ NCT02519855 ↗ NCT05519839 ↗
Known as	Influenza Vaccine 2004-2005 Paediatric Formulation	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00831675 ↗
Known as	Influenza Virus Vaccine(contains Preservative)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01551823 ↗
Known as	Influenza Virus Vaccine, Fluzone	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00390884 ↗
Known as	Influenzae vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03109600 ↗ 1 NCT00812110 ↗
Known as	Influsplit SSW	“the Fluarix™/Influsplit SSW® influenza vaccine containing the influenza strains recommended for the 2010-2011 season” NCT01144299 ↗ 3 “Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in People 18 Years Old or Above” NCT00476307 ↗ “Fluarix™ (Influsplit SSW®) 2006/2007” NCT00345904 ↗ “Fluarix™/Influsplit SSW®” NCT00920374 ↗
Known as	Influvac	“The current study is a phase IIIa clinical trial with a commercially available vaccine (Influvac®) supplied in pre filled syringes.” NCT00479921 ↗ 15 “A single standard dose of inactivated trivalent influenza vaccine: Influvac® vaccines (Abbott, the Netherlands), intramuscularly.” NCT04122222 ↗ “The details of using Influvac vaccine of that year are produced by Abbott.” NCT05070494 ↗ “surface antigen, inactivated, prepared in egg (influvac ®)” NCT01013675 ↗ “surface antigen, inactivated, prepared in egg (influvac ®)” NCT00999206 ↗ “commercially available vaccine (Influvac®)” NCT02381418 ↗ “vaccine (FLuarix, Influvac etc)” NCT00679237 ↗ “Influvac” NCT01119157 ↗ NCT00325260 ↗ NCT00346723 ↗ NCT01633749 ↗ NCT00881842 ↗ NCT02381418 ↗ NCT01146015 ↗ NCT00665509 ↗ NCT00371098 ↗
Known as	MF59-adjuvanted vaccine	“MF59-adjuvanted vaccine (Sub/MF59, n = 130)” PMID 19561422 ↗ Jul 2009
Known as	Purethal	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02440243 ↗
Known as	QIV	“This study evaluated coadministration of 20-valent pneumococcal conjugate vaccine (PCV20) and an adjuvanted quadrivalent inactivated influenza vaccine (QIV).” PMID 36828719 ↗ Feb 2023 1 “In contrast, the quadrivalent influenza vaccine (QIV) generates an immunity that wanes quickly with no long-lasting protection.” NCT05801978 ↗
Known as	QIV-HD	“High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation” NCT04024228 ↗
Known as	QuadriFlu - TIV	“Fluzone® (QuadriFlu - TIV), inactivated, quadrivalent influenza vaccine” NCT03926416 ↗
Known as	quadrivalent inactivated influenza vaccine	“Quadrivalent Inactivated Influenza Vaccine Intramuscular (Fluarix Tetra)” NCT03502291 ↗ 8 “quadrivalent inactivated influenza vaccine (IIV4)” NCT04559204 ↗ “quadrivalent inactivated influenza vaccine (IIV4)” NCT05028361 ↗ “IIV4 (quadrivalent inactivated influenza vaccine)” NCT06503900 ↗ NCT03888989 ↗ NCT03179761 ↗ NCT04697576 ↗ NCT05144945 ↗ NCT03969641 ↗
Known as	Quadrivalent inactivated influenza vaccine (IIV)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03898973 ↗
Known as	quadrivalent influenza split-virion vaccine	“This study assessed the immunogenicity and safety of a quadrivalent influenza split-virion vaccine (IIV4) in children with and without prior influenza vaccination.” PMID 39993940 ↗ Feb 2025
Known as	Quadrivalent seasonal influenza vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06024096 ↗ 1 NCT05801978 ↗
Known as	quadrivalent split-virion inactivated influenza vaccine	“an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine” PMID 35931636 ↗ Jul 2022
Known as	Quadrivalent, inactivated influenza vaccine (IIV4)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01827462 ↗
Known as	rHSC-DIPGVax	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04943848 ↗
Known as	SD Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01815268 ↗
Known as	seasonal TIV	“received 1 dose of seasonal TIV and 2 doses of 2009 H1N1 vaccine” PMID 22802432 ↗ Jul 2012
Known as	seasonal trivalent inactivated influenza vaccine	“seasonal trivalent inactivated influenza vaccine (TIV; split virion)” PMID 22802432 ↗ Jul 2012 2 NCT01819155 ↗ NCT00893906 ↗
Known as	Sequiris Fluad Quad	“Influenza vaccine (Sequiris Fluad Quad)” NCT07587801 ↗
Known as	SIIV	“Seasonal inactivated influenza vaccine (SIIV)” NCT04526574 ↗
Known as	split vaccine	“nonadjuvanted split vaccine (split, n = 139)” PMID 19561422 ↗ Jul 2009
Known as	Split, Inactivated, Trivalent Influenza Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00391391 ↗ 1 NCT00388583 ↗
Known as	Standard dose influenza vaccination	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04487041 ↗
Known as	Standard Dose Quadrivalent Inactivated Influenza Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05215327 ↗ 1 NCT04613206 ↗
Known as	Standard Trivalent Influenza Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01666782 ↗
Known as	Sub/MF59	“MF59-adjuvanted vaccine (Sub/MF59, n = 130)” PMID 19561422 ↗ Jul 2009
Known as	TIV	“This randomized, placebo controlled trial will evaluate the safety and immunogenicity of Trivalent Influenza Vaccine (TIV) in HIV-infected pregnant women, dynamics of...” NCT01306682 ↗ 21 “Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly...” NCT00492557 ↗ “Either a standard pediatric dose (0.25 ml) or a larger dose (0.5 ml) of Trivalent Inactivated Influenza Vaccine (TIV) (Fluzone®) administered intramuscularly (IM) in the thigh...” NCT01164553 ↗ “This is a phase I safety and immunogenicity trial comparing high-dose (HD)trivalent inactivated influenza vaccine (TIV) to standard dose (SD) TIV in pediatric patients with...” NCT01216332 ↗ “One child aged 6-17 years in each of 796 households was randomized to receive 2009-2010 seasonal trivalent inactivated influenza vaccine (TIV) or saline placebo between August...” PMID 22670050 ↗ Jun 2012 “We examined serum cytokine kinetics following inactivated trivalent influenza vaccine (TIV) to better understand potential relationships between markers of inflammation and...” PMID 28991404 ↗ Jan 2018 “In this study we describe the immunogenicity results from a subset of older people (N = 5187) who participated in a Phase 3 randomized, observer-blinded trial of AS03-TIV...” PMID 27690762 ↗ Dec 2016 “Single 0.5 ml 23-valent pneumococcal polysaccharide vaccine (23vPPV) and a single 0.5 ml trivalent inactivated influenza vaccine (TIV) were administered IM, in one day.” NCT02062281 ↗ “vaccination with either live trivalent influenza vaccine (LAIV) or trivalent influenza vaccine (TIV) in healthy children between the ages of 2 and 9 years.” NCT01246999 ↗ “Two doses of trivalent inactivated influenza vaccine (TIV) are recommended for children <9 years old receiving vaccine for the first time” PMID 16991077 ↗ Sep 2006 “Licensed trivalent influenza vaccine (TIV) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.” NCT00943878 ↗ “Age appropriate dose of seasonal Trivalent Influenza Vaccine (TIV), either 0.25mL under age 3 or 0.5mL over the age of 3.” NCT01264601 ↗ “A single dose of trivalent inactivated influenza vaccine (TIV) is 70 to 90 percent effective in preventing influenza” NCT00893906 ↗ “trivalent inactivated influenza vaccine (TIV, Fluzone®, sanofi pasteur 2005-6 pediatric formulation)” NCT00242424 ↗ “The seasonal flu vaccine that the researchers are using is called trivalent influenza vaccine (TIV).” NCT00987350 ↗ “0.5 ml of Inactivated Trivalent Influenza Vaccine (TIV), Fluzone® given intramuscularly (IM)” NCT01181323 ↗ “0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)” NCT00956202 ↗ “seasonal trivalent inactivated influenza vaccine (TIV; split virion)” PMID 22802432 ↗ Jul 2012 “Participants will receive the Trivalent Influenza Vaccine (TIV).” NCT01481454 ↗ “non-adjuvanted trivalent influenza vaccine (TIV) formulations” PMID 24732325 ↗ Apr 2014 “trivalent inactivated influenza vaccine (TIV)” NCT07493460 ↗ “trivalent inactivated influenza vaccine (TIV)” PMID 22739693 ↗ Jun 2012
Known as	trivalent inactivated influenza vaccine	“METHODS: We conducted two double-blind, randomized, placebo-controlled trials of trivalent inactivated influenza vaccine (IIV3) in South Africa during 2011 in pregnant women...” PMID 25184864 ↗ Sep 2014 24 “Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly...” NCT00492557 ↗ “Two doses of trivalent inactivated influenza vaccine (TIV) are recommended for children <9 years old receiving vaccine for the first time” PMID 16991077 ↗ Sep 2006 “Licensed trivalent inactivated influenza vaccine” NCT02263027 ↗ “trivalent inactivated influenza vaccine (TIV)” PMID 22739693 ↗ Jun 2012 NCT01427309 ↗ NCT00115531 ↗ NCT01319955 ↗ NCT00943878 ↗ NCT00766285 ↗ NCT01522248 ↗ NCT00161122 ↗ NCT01258595 ↗ NCT00570037 ↗ NCT01216332 ↗ NCT00402805 ↗ NCT01164553 ↗ NCT00943202 ↗ NCT01811823 ↗ NCT00133523 ↗ NCT01436370 ↗ NCT01812980 ↗ NCT00961337 ↗ NCT00307177 ↗ NCT00170547 ↗
Known as	trivalent inactivated influenza vaccine (TIV)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07493460 ↗ 1 NCT01827462 ↗
Known as	Trivalent Influenza Vaccine	“0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)” NCT00956202 ↗ 24 NCT02860039 ↗ NCT02249221 ↗ NCT03179761 ↗ NCT00022035 ↗ NCT01561989 ↗ NCT04080531 ↗ NCT00987350 ↗ NCT06252051 ↗ NCT03336593 ↗ NCT02882100 ↗ NCT01481454 ↗ NCT01863433 ↗ NCT02473510 ↗ NCT01859143 ↗ NCT01306669 ↗ NCT01306682 ↗ NCT01695733 ↗ NCT02062281 ↗ NCT01246999 ↗ NCT01816464 ↗ NCT01941758 ↗ NCT01264601 ↗ NCT02518555 ↗ NCT00848848 ↗
Known as	Trivalent influenza vaccine (seasonal)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01527825 ↗
Known as	Trivalent influenza vaccine (TIV)	“0.5 mL of a trivalent influenza vaccine (TIV) at Month 13” NCT00956046 ↗ 2 NCT02550197 ↗ NCT01232868 ↗
Known as	trivalent split-virion inactivated influenza vaccine	“BACKGROUND: Few data exist on the immunogenicity and safety of an inactivated enterovirus 71 vaccine (EV71 vaccine) coadministered with trivalent split-virion inactivated...” PMID 36569946 ↗ Dec 2022
Known as	Trivalent Subviron Influenza vaccine	“Trivalent Subviron Influenza vaccine (Fluzone)” NCT00133510 ↗
Known as	UBC	“umbilical cord blood (UBC)” NCT01768845 ↗
Known as	UCB	“Umbilical cord blood (UCB) is collected following labor and is transfused intravenously within 48 hours after the birth.” NCT03352310 ↗ 4 “followed by umbilical cord blood (UCB) infusion in elderly patients with AML.” PMID 31429724 ↗ Aug 2019 “unrelated umbilical cord blood (UCB)” NCT00604201 ↗ “umbilical cord blood (UCB)” NCT01768845 ↗ NCT05577611 ↗
Known as	umbilical cord blood	“Compared with peripheral blood / bone marrow hematopoietic stem cells, umbilical cord blood (UCB) hematopoietic stem cells have the advantages of rapid access, convenient...” NCT05577611 ↗ 16 “The primary purpose of this protocol is to enable access to autologous (a person's own) or allogeneic (someone else's) umbilical cord blood infusion for children with various...” NCT03327467 ↗ NCT01622556 ↗ NCT04013646 ↗ NCT03352310 ↗ NCT05794425 ↗ NCT02050971 ↗ NCT01601158 ↗ NCT01193660 ↗ NCT05669079 ↗ NCT04687657 ↗ NCT01768845 ↗ NCT01962636 ↗ NCT07201233 ↗ NCT03004976 ↗ NCT00676806 ↗ NCT00604201 ↗
Known as	Unrelated cord blood	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03913312 ↗ 1 NCT02127892 ↗
Known as	US Licensed Influenza Virus Vaccine	“US Licensed Influenza Virus Vaccine (Fluzone®)” NCT00735475 ↗
Known as	Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01896869 ↗
Known as	Vaxigrip	“Round 2 (May): 0.5mL Vaxigrip®, Sanofi Pasteur, containing 45μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the southern...” NCT02957890 ↗ 27 “1 dose (0.5 mL) of VAXIGRIP and 1 dose (0.5 mL) of REPEVAX in 2 separate injections sites (1 on each arm)” NCT01249183 ↗ “To describe the humoral immune response to Vaxigrip (IM) vaccination at Day 0 (baseline) and Day 28” NCT03266237 ↗ “The regular seasonal trivalent Influenza vaccine( Vaxigrip) will be diluted 1:10 in saline.” NCT00758212 ↗ “standard trivalent intramuscular (IM) vaccine (Vaxigrip® 15 μg, Sanofi Pasteur)” PMID 25483667 ↗ 2014 “Injection of the conventional flu vaccine: Vaxigrip to all study participants.” NCT01010737 ↗ “Vaxigrip - Seasonal Influenza, split virion, inactivated vaccine.” NCT03016143 ↗ “MUTAGRIP (2009-2010 winter) VAXIGRIP (2010-2011 winter)” NCT01022749 ↗ “Vaxigrip” NCT01119157 ↗ NCT01916759 ↗ NCT01000584 ↗ NCT01215669 ↗ NCT01707602 ↗ NCT01665807 ↗ NCT02263131 ↗ NCT01368796 ↗ NCT07604103 ↗ NCT00760175 ↗ NCT05470582 ↗ NCT02645032 ↗ NCT03016143 ↗ NCT02640989 ↗ NCT01967368 ↗ NCT00778895 ↗ NCT06286488 ↗ NCT00386542 ↗ NCT03266237 ↗ NCT01180699 ↗
Known as	Vaxigrip 2009/2010	“Group A: Single dose of Arepanrix and single dose of Vaxigrip 2009/2010 given concurrently” NCT01000584 ↗
Known as	VAXIGRIP Prefilled Syringe INJ.	“VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL” NCT02263131 ↗
Known as	VaxigripTetra	“Name of investigational treatment: Influenza vaccine (VaxigripTetra, Sanofi Pasteur MSD).” NCT02831608 ↗
Action	Restore	“can restore the bone marrow” NCT01768845 ↗
Modality	Vaccine	“Influenza Virus Vaccine” NCT00001080 ↗
Route	Intramuscular	“a single intramuscular injection” NCT00006146 ↗